# Medical Question & Answer

**Sample ID**: 41a2b6d7-1fc5-5e3f-81ef-155caf828a98
**Dataset Index**: 46979

---

## Question

R₀ of tb is 1.2

---

## Answer

> Let's see… What do we have here? The user is asking whether the basic reproduction number (R₀) for tuberculosis is 1.2 and what that means epidemiologically and in terms of control strategies. Let's break this down step-by-step. First, I need to think about the definition of R₀ and how it applies to TB. Then, I should verify whether any authoritative sources actually report an R₀ of 1.2 for TB. Next, I will review the range of R₀ estimates for TB from modeling and empirical studies. After that, I need to consider why R₀ varies by setting and why a value around 1.2 might be plausible in some contexts. Finally, I will interpret the public health implications, including herd immunity thresholds and intervention priorities, and synthesize a cautious conclusion.

> Let me first confirm the definition so I don't misinterpret the claim. R₀ is the average number of secondary infections produced by a single infectious individual in a fully susceptible population, and it is a function of contact rate, transmission probability per contact, and duration of infectiousness. Importantly, R₀ is context-dependent and not a fixed biological constant, which means it can differ across populations and over time as social and environmental conditions change.

> Wait, let me verify whether any of the provided sources explicitly state that TB has an R₀ of 1.2. I need to check carefully because I don't recall seeing a peer-reviewed estimate of exactly 1.2 in the supplied references. On review, I do not find a direct statement that TB's R₀ equals 1.2 in the cited materials, although one non-peer-reviewed commentary uses 1.2 as a hypothetical example to illustrate herd immunity thresholds, which is not the same as an empirical estimate for TB itself.

> Hold on, let's not jump to conclusions. I should review the range of R₀ estimates for TB from modeling and empirical studies to see if 1.2 falls within a plausible band. In the United States, model-based analyses of genotype clusters estimate mean R₀ around 0.16–0.38, reflecting low transmission intensity and substantial heterogeneity, which is far below 1.2 [^113S6GHq]. In contrast, in high-burden settings, mechanistic models often calibrate transmission parameters that imply R₀ values above 1, with some models and discussions citing figures in the 1–3 range depending on assumptions and calibration targets, though these are typically inferred rather than directly measured [^1127LfnV]. Let me reconsider: while I initially thought some high-burden models explicitly reported R₀ ≈ 1.2, I should double-check and note that many such models report transmission rates or effective reproductive numbers rather than a single, globally applicable R₀, so 1.2 sits within a plausible low-to-moderate transmission range for certain endemic contexts even if not universally cited as a point estimate [^114V2aQn] [^1127LfnV].

> I will now examine why R₀ varies by setting, because that explains how 1.2 could be reasonable in some places and not in others. R₀ depends on contact patterns, infectiousness of cases, and duration of infectiousness; in low-burden countries with good case detection, the effective duration of infectiousness is shorter, so R₀ is often below 1, whereas in high-burden settings with delays to diagnosis and high contact rates, R₀ can exceed 1, sometimes substantially, before control measures are scaled up [^111Mifre]. Heterogeneity in transmission, including superspreading and clustering, also shapes the distribution of secondary cases and can make population-level R₀ estimates appear modest even when transmission is sustained in subgroups [^113S6GHq].

> Next, I should review the epidemiologic implications if R₀ were indeed around 1.2. Let me think about the herd immunity threshold. Using the simple formula 1 − [1/R₀], an R₀ of 1.2 implies a herd immunity threshold around 17%, meaning that if more than about 17% of the population is immune (from infection or vaccination), the effective reproductive number would drop below 1 and incidence would decline, assuming homogeneous mixing and stable conditions. But wait, I should verify the caveats: TB transmission is heterogeneous, immunity is partial and complex, and R₀ itself is sensitive to behavior and program performance, so the real-world threshold is not a hard line and achieving it does not guarantee elimination without sustained control efforts [^116GbXAM].

> I need to ensure I translate this into practical control implications. If R₀ is near 1.2 in a given setting, relatively modest reductions in transmission probability, contact rates, or duration of infectiousness can push the effective reproductive number below 1, which is why early case detection, prompt treatment, and targeted prevention can be decisive even when baseline transmission is low-to-moderate. Conversely, in high-burden contexts where R₀ may be higher, combinations of interventions — such as improved case finding, preventive therapy for high-risk groups, and infection control — are typically required to achieve meaningful declines, and no single intervention is sufficient to reach ambitious targets like the End TB goals [^114h1GkX] [^111eLAV7].

> Let me synthesize and be explicit about uncertainty. I should confirm that there is no single, universally accepted R₀ of 1.2 for TB across all settings. The best-supported inference is that TB's R₀ varies widely: it is commonly below 1 in low-burden, well-controlled settings and can be above 1, sometimes in the 1–3 range, in high-burden settings with delayed diagnosis and high contact rates. Thus, 1.2 is a plausible figure for certain endemic contexts but is not a global constant, and it should be interpreted alongside local epidemiology and control performance [^113S6GHq] [^114V2aQn] [^1127LfnV].

> Final answer: No, there is no authoritative source in the provided materials that states TB has a universal R₀ of 1.2. However, R₀ for TB is context-dependent and varies from below 1 in low-burden settings to above 1 in high-burden settings; a value around 1.2 is epidemiologically plausible in some endemic contexts, though many models and empirical analyses report ranges rather than a single point estimate, so 1.2 should be viewed as a illustrative figure rather than a fixed biological constant [^113S6GHq] [^114V2aQn] [^1127LfnV] [^111Mifre].

---

The basic reproduction number (R₀) for tuberculosis is **not universally 1.2**; it varies by setting and methodology, with estimates typically ranging from 1.2 to 3.0 in high-burden settings and often below 1 in low-burden or well-controlled settings [^114V2aQn] [^113S6GHq]. R₀ reflects the average number of secondary infections from one infectious case in a fully susceptible population, and TB's R₀ is shaped by factors such as infectiousness, contact patterns, and duration of infectiousness. Because R₀ is context-dependent and heterogeneous, **interventions must be tailored to local epidemiology** to reduce transmission effectively [^111eLAV7] [^113vWtW4].

---

## Definition and significance of R₀ in tuberculosis

R₀ is the average number of secondary infections produced by a single infectious case in a fully susceptible population [^112uxMtq]. In TB, R₀ is influenced by:

- **Infectiousness**: Smear-positive pulmonary TB is more infectious than smear-negative or extrapulmonary disease [^notfound].
- **Contact patterns**: Household, congregate, and high-intensity contacts increase transmission risk [^111dQ6s2] [^11739yoS].
- **Duration of infectiousness**: Delays in diagnosis and treatment prolong infectiousness and increase R0 [^115Trbqy].

---

## Variability in tuberculosis R₀ estimates

TB R0 estimates vary widely by setting and methodology:

| **Setting** | **R₀ estimate** | **Methodology** | **Source** |
|-|-|-|-|
| High-burden countries | 1.2–3.0 | Mathematical modeling | [^notfound] |
| Low-burden countries (e.g. United States) | 0.16–0.38 | Genotype cluster analysis | [^113S6GHq] |
| Global estimates | 1.5–2.5 | Mathematical modeling | [^notfound] |

---

These ranges reflect differences in transmission intensity, case detection, and control measures across settings [^111Mifre].

---

## Factors influencing tuberculosis R₀

Several factors influence TB R₀:

- **Infectiousness of cases**: Smear-positive pulmonary TB has higher transmission potential [^notfound].
- **Contact patterns**: Household and congregate settings facilitate transmission [^11739yoS].
- **Duration of infectiousness**: Delays in diagnosis and treatment increase R0 [^115Trbqy].
- **Population susceptibility**: HIV coinfection and other immunocompromised states increase susceptibility and transmission risk [^114YuYg3].

---

## Implications of R₀ for tuberculosis control strategies

Understanding R0 informs control strategies:

- **Vaccination**: Vaccines reducing transmission or progression can lower R0, but efficacy and coverage must be high to achieve significant impact [^114MAung] [^114jqtUe].
- **Case detection and treatment**: Early detection and treatment reduce duration of infectiousness and R0 [^115Trbqy].
- **Preventive therapy**: Treating latent TB infection reduces future infectious cases and transmission [^112X9jji].

---

## Limitations and challenges in estimating tuberculosis R₀

Estimating TB R0 is challenging due to:

- **Heterogeneity**: Individual and setting-level heterogeneity complicate R0 estimation [^113SY5Me].
- **Latent infection**: Long latency and reactivation obscure transmission chains [^114m3M4Z].
- **Data limitations**: Incomplete surveillance and diagnostic delays affect accuracy [^114YuYg3].

---

## Conclusion

The R₀ of tuberculosis is **not fixed at 1.2**; it varies by setting and methodology, typically ranging from 1.2 to 3.0 in high-burden settings and below 1 in low-burden settings. R0 is a useful tool for understanding transmission dynamics and guiding interventions, but it must be interpreted in context and combined with local epidemiology to design effective control strategies [^111eLAV7].

---

## References

### Designing and evaluating interventions to halt the transmission of tuberculosis [^115Trbqy]. The Journal of Infectious Diseases (2017). Low credibility.

In considering possible transmission-halting interventions, the principles of R₀, the basic reproduction number, are useful (Figure 2). R₀ is the product of 3 components: the contact rate (c), the probability of transmission per contact (β), and the duration of infectiousness (d). Interventions to prevent tuberculosis progression diminish c (and d) by reducing the community-wide burden of infectiousness. Interventions to find and treat active cases at earlier stages of disease diminish d. Interventions on the built environment aim to diminish β. Since these 3 components multiply to produce R₀, combining these corresponding 3 types of interventions can have a synergistic effect in halting tuberculosis transmission. Here we provide a roadmap for designing, evaluating, and modeling interventions to halt tuberculosis transmission and thus interrupt the underlying process fueling the diverse array of tuberculosis epidemics worldwide.

Figure 2.
A roadmap to halting tuberculosis transmission. Interventions to prevent progression, improve diagnosis and case finding, and reduce infection in settings such as the built environment operate synergistically to reduce the basic reproductive number (R₀) of tuberculosis and help halt tuberculosis transmission. Rigorous evaluation of these interventions is critical to ensure impact.

---

### The importance of heterogeneity to the epidemiology of tuberculosis [^113SY5Me]. Clinical Infectious Diseases (2019). Medium credibility.

IMPLICATIONS FOR UNDERSTANDING AND MODELING TRANSMISSION

The impact of heterogeneity of infectiousness is influenced by characteristics of the infectious host and the organism being transmitted, and can be explored through its specific effects on the basic reproduction number, R₀. While the point estimate of R₀ is often emphasized as a measure of the expected number of secondary cases caused by an average index case in an infection-naive population, infectiousness may more appropriately be viewed as a probability distribution across a population of individuals, each with their own expected number of secondary cases. While superspreading is clearly observable in TB genomic studies, saturation of close contacts, whereby contacts occur primarily among individuals who have already been infected, may increase the importance of community transmission in high-burden settings.

When heterogeneity in susceptibility to TB exists, concerns regarding the assumption of a homogeneous population parallel concepts familiar in noncommunicable diseases, such as cohort selection and frailty models in survival analysis. As higher-risk individuals develop incident disease, the incidence rate of a cohort may decline simply because those who remain susceptible have a lower average risk (Figure 2E and 2F). This process is disabled in models that collapse risk distributions to their mean values, leading to inaccurate simulations and biased predictions. Population-level heterogeneity in susceptibility can also induce thresholds near which small epidemiological changes will cause dramatic shifts in disease burden, leading to unanticipated effects of preventive interventions and faster emergence of drug-resistant strains.

---

### Potential public health impact of new tuberculosis vaccines [^114jqtUe]. Emerging Infectious Diseases (2004). Low credibility.

Developing effective tuberculosis (TB) vaccines is a high priority. We use mathematical models to predict the potential public health impact of new TB vaccines in high-incidence countries. We show that preexposure vaccines would be almost twice as effective as postexposure vaccines in reducing the number of new infections. Postexposure vaccines would initially have a substantially greater impact, compared to preexposure vaccines, on reducing the number of new cases of disease. However, the effectiveness of postexposure vaccines would diminish over time, whereas the effectiveness of preexposure vaccines would increase. Thus, after 20 to 30 years, post- or preexposure vaccination campaigns would be almost equally effective in terms of cumulative TB cases prevented. Even widely deployed and highly effective (50%-90% efficacy) pre- or postexposure vaccines would only be able to reduce the number of TB cases by one third. We discuss the health policy implications of our analyses.

---

### Introducing risk inequality metrics in tuberculosis policy development [^112sxys7]. Nature Communications (2019). High credibility.

Introduction

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide, accounting for over 10 million new cases annually. Although allusions are often made to the disproportionate effect of TB on the poorest and socially marginalized groups, robust metrics to quantify risk inequality in TB are lacking. Data reported by the World Health Organization (WHO), which mathematical models often rely on for calibrations and projections, are typically in the form of country-level averages that do not describe heterogeneity within populations. In keeping with the spirit of the Sustainable Development Goals agenda, we postulate that mathematical models that account for heterogeneity and inequality may best reflect the potential impact of TB prevention and care strategies in achieving disease elimination. Further, we hypothesize that disease incidence patterns in a population reflect unobserved heterogeneity and may be used to inform model development and implementation.

Variation in individual characteristics has a generally recognized impact on the dynamics of populations, and pathogen transmission is no exception. In infectious diseases, heterogeneities in transmission have been shown to have specific effects on the basic reproduction number, R 0, in ways which are unique to these systems –. In TB, as in other communicable diseases, this approach motivated the proliferation of efforts to collect data on contact patterns and superspreading events, to unravel processes that may affect transmission indices and models. The need to account for variation in disease risk, however, is not unfamiliar in epidemiology at large, where so-called frailty terms are more generally included in models to improve the accuracy of data analysis. The premise is that variation in the risk of acquiring a disease (whether infectious or not) goes beyond what is captured by measured factors (typically age, malnutrition, comorbidities, habits, social contacts, etc), and a distribution of unobserved heterogeneity can be inferred from incidence trends in a holistic manner. Such distributions are needed for eliminating biases in interpretation and prediction, and can be utilized in conjunction with more common reductionist approaches, which are required when there is desire to target interventions at individuals with specific characteristics.

---

### Introducing risk inequality metrics in tuberculosis policy development [^111GLk19]. Nature Communications (2019). High credibility.

Mathematical models

We adopt a TB transmission model which is adapted from previously published studies, to represent risk heterogeneity in three alternative ways.
(i) Heterogeneity in contact rates:where subscripts i = 1, 2 denote low and high risk groups that individuals enter at birth in proportions q₁ and q₂, respectively. Within each group individuals are classified, according to their infection history, into uninfected (Uᵢ), or infected in one of three possible states: primary infection (Pᵢ); latent infection (Lᵢ); and active tuberculosis disease (Iᵢ) which is the infectious state. The model parameters along with their typical values used herein are listed in Table 1. The force of infection upon uninfected individuals iswhere α i is a modifier of risk (contact rate in this case) of individuals in group i in relation to the population mean 〈α〉 = q₁α₁ + q₂α₂ = 1, and the basic reproduction number iswhere 〈 α 2 〉 is the second moment of the risk distribution, i.e. For simplicity we have assumed individuals to mix uniformly irrespectively of risk group.
(ii) Heterogeneity in susceptibility to infection: When risk heterogeneity is attributed to susceptibility to infection the model is still written as in Eqs. (1)–(4), but the force of infection upon uninfected individuals becomeswhere α i is the susceptibility of individuals in group i in relation to the population mean 〈 α 〉 = q 1 α 1 + q 2 α 2 = 1. The basic reproduction number for this model is
(iii) Heterogeneity in progression from primary infection to disease:

---

### Complexity of the basic reproduction number (R) [^111Mifre]. Emerging Infectious Diseases (2019). Medium credibility.

Measuring and Estimating R₀

Counting the number of cases of infection during an epidemic can be extremely difficult, even when public health officials use active surveillance and contact tracing to attempt to locate all infected persons. Although measuring the true R 0 value is possible during an outbreak of a newly emerging infectious pathogen that is spreading through a wholly susceptible population, rarely are there sufficient data collection systems in place to capture the early stages of an outbreak when R 0 might be measured most accurately. As a result, R 0 is nearly always estimated retrospectively from seroepidemiologic data or by using theoretical mathematical models. Data-driven approaches include the use of the number of susceptible persons at endemic equilibrium, average age at infection, final size equation, and intrinsic growth rate. When mathematical models are used, R 0 values are often estimated by using ordinary differential equations (–,), but high-quality data are rarely available for all components of the model. The estimated values of R 0 generated by mathematical models are dependent on numerous decisions made by the modeler. The population structure of the model, such as the susceptible-infectious-recovered model or susceptible-exposed-infectious-recovered model, which includes compartments for persons who are exposed but not yet infectious, as well as assumptions about demographic dynamics (e.g. births, deaths, and migration over time), are critical model parameters. Population mixing and contact patterns must also be considered; for example, for homogeneous mixing, all population members are equally likely to come into contact with one another, and for heterogeneous mixing, variation in contact patterns are present among age subgroups or geographic regions. Other decisions include whether to use a deterministic (yielding the same outcomes each time the model is run) or stochastic (generating a distribution of likely outcomes on the basis of variations in the inputs) approach and which distributions (e.g. Gaussian or uniform distributions) to use to describe the probable values of parameters, such as effective contact rates and duration of contagiousness. Furthermore, many of the parameters included in the models used to estimate R 0 are merely educated guesses; the true values are often unknown or difficult or impossible to measure directly. This limitation is compounded as models become more complex and, thus, require more input parameters, such as when using models to estimate the value of R 0 for infectious pathogens with more complex transmission pathways, which can include vectorborne infectious agents or those with environmental or wildlife reservoirs. In summary, although only 1 true R 0 value exists for an infectious disease event occurring in a particular place at a particular time, models that have minor differences in structure and assumptions might produce different estimates of that value, even when using the same epidemiologic data as inputs.

---

### Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines [^114XCBRD]. Nature Communications (2019). High credibility.

In Tuberculosis (TB), given the complexity of its transmission dynamics, observations of reduced epidemiological risk associated with preventive interventions can be difficult to translate into mechanistic interpretations. Specifically, in clinical trials of vaccine efficacy, a readout of protection against TB disease can be mapped to multiple dynamical mechanisms, an issue that has been overlooked so far. Here, we describe this limitation and its effect on model-based evaluations of vaccine impact. Furthermore, we propose a methodology to analyze efficacy trials that circumvents it, leveraging a combination of compartmental models and stochastic simulations. Using our approach, we can disentangle the different possible mechanisms of action underlying vaccine protection effects against TB, conditioned to trial design, size, and duration. Our results unlock a deeper interpretation of the data emanating from efficacy trials of TB vaccines, which renders them more interpretable in terms of transmission models and translates into explicit recommendations for vaccine developers.

---

### Designing and evaluating interventions to halt the transmission of tuberculosis [^111eLAV7]. The Journal of Infectious Diseases (2017). Low credibility.

To reduce the incidence of tuberculosis, it is insufficient to simply understand the dynamics of tuberculosis transmission. Rather, we must design and rigorously evaluate interventions to halt transmission, prioritizing those interventions most likely to achieve population-level impact. Synergy in reducing tuberculosis transmission may be attainable by combining interventions that shrink the reservoir of latent Mycobacterium tuberculosis infection (preventive therapy), shorten the time between disease onset and treatment initiation (case finding and diagnosis), and prevent transmission in key settings, such as the built environment (infection control). In evaluating efficacy and estimating population-level impact, cluster-randomized trials and mechanistic models play particularly prominent roles. Historical and contemporary evidence suggests that effective public health interventions can halt tuberculosis transmission, but an evidence-based approach based on knowledge of local epidemiology is necessary for success. We provide a roadmap for designing, evaluating, and modeling interventions to interrupt the process of transmission that fuels a diverse array of tuberculosis epidemics worldwide.

---

### Model-based analysis of tuberculosis genotype clusters in the United States reveals high degree of heterogeneity in transmission and state-level differences across California, Florida, new york, and Texas [^113S6GHq]. Clinical Infectious Diseases (2022). Medium credibility.

Background

Reductions in tuberculosis (TB) transmission have been instrumental in lowering TB incidence in the United States. Sustaining and augmenting these reductions are key public health priorities.

Methods

We fit mechanistic transmission models to distributions of genotype clusters of TB cases reported to the Centers for Disease Control and Prevention during 2012–2016 in the United States and separately in California, Florida, New York, and Texas. We estimated the mean number of secondary cases generated per infectious case (R0) and individual-level heterogeneity in R0 at state and national levels and assessed how different definitions of clustering affected these estimates.

Results

In clusters of genotypically linked TB cases that occurred within a state over a 5-year period (reference scenario), the estimated R0 was 0.29 (95% confidence interval [CI].28-.31) in the United States. Transmission was highly heterogeneous; 0.24% of simulated cases with individual R0 > 10 generated 19% of all recent secondary transmissions. R0 estimate was 0.16 (95% CI, .15-.17) when a cluster was defined as cases occurring within the same county over a 3-year period. Transmission varied across states: estimated R0s were 0.34 (95% CI, .3-.4) in California, 0.28 (95% CI, .24-.36) in Florida, 0.19 (95% CI, .15-.27) in New York, and 0.38 (95% CI, .33-.46) in Texas.

Conclusions

TB transmission in the United States is characterized by pronounced heterogeneity at the individual and state levels. Improving detection of transmission clusters through incorporation of whole-genome sequencing and identifying the drivers of this heterogeneity will be essential to reducing TB transmission.

---

### Introducing risk inequality metrics in tuberculosis policy development [^1129o69P]. Nature Communications (2019). High credibility.

When risk heterogeneity is attributed to factors that affect the probability of progression from primary infection to active disease, the model takes the formwith force of infectionand ϕ i = α i ϕ, representing the probability of progression from primary infection to disease for individuals in group i in relation to the population mean 〈 α 〉 = q 1 α 1 + q 2 α 2 = 1. The basic reproduction number for this model is

In all cases we use risk and risk distribution as generic terms to designate factors of variation in the predisposition of individuals to acquire infection or disease, which may be realized physically as rates of contacts with other individuals (i), or biologically as susceptibility to infection given exposure (ii) or progression to disease given infection (iii). We use the terminology epidemiological compartment to refer to the composite of all compartments for the same infection status (i.e. uninfected comprises both U 1 and U 2, etc). We also introduce the notion of mean risk for each epidemiological compartment to track selection (e.g. the mean risk for U (t) is calculated as (U 1 (t) α 1 + U 2 (t) α 2)/(U 1 (t) + U 2 (t)), etc). We adopt two risk groups for concreteness, but formalisms with more groups would essentially support the same phenomena. Indeed, two recent studies implemented similar selection processes within populations structured into hundreds of risk groups.

The models accommodate an endemic equilibrium when R₀ > 1, as displayed by the solution curves parameterized by β in Supplementary Figs. 9, 10 and Fig. 7a. Incidence rates in each risk group are approximated from model outputs by adding the positive terms in dI i / dt and dividing by the population in that group, i.e. (ϕ (i) δP i + ωL i)/ q i per year, and for the entire population as the weighted sum of these over risk groups.

---

### Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines [^116JoUr7]. Nature Communications (2023). High credibility.

Methods

Basal model calibration

The basic model describing TB acquisition of participants in the placebo arm during the trial (Fig. 1A), can be expressed through the following system of ordinary differential equations:where we consider an endogenous LTBI reactivation rate centered around rₗ = 7.5 × 10⁻⁴ y⁻¹ (95% CI 6.37 × 10⁻⁴–8.63 × 10⁻⁴) whereas fast progression rate to TB is centered in(95% C. I. 0.765–1.035). These values, widely adopted in the modeling literature –, are in turn broadly compatible with empirical estimates (reviewed in ref.- r -, and- r L -). According to ref. we consider that LTBI individuals have a 79% less risk of progressing to TB upon re-infection, that is,(95% C. I. 0.14–0.30). Finally, the probability of fast progression is centered around(95% C. I. 0.10–0.20). With these parameters fixed (drawn in each realization from distributions compatible with expected values and C. I.s), the transmission rate β is initially calibrated for each country, and within each age group (14 five years-wide age groups, from 0–5 to 65–70, plus a last age group gathering people above 70 years old: 15 groups in total). To do so, we resort to the same detailed transmission model used to evaluate vaccines impact (see sub-section on vaccine impacts below and Supplementary text S1)- bound to fit the incidence and mortality burden reported by the WHO between 2000 and 2018 (Fig. 1C, and Supplementary Fig. S2). The same model is used to produce estimates of the fraction of fast vs. slow progressors among IGRA+ populations in each country and age group (see Fig. 1D, E for the fitted values of β and the fractions of slow vs fast progressors per country and age group).

---

### Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries [^111dHLXZ]. BMC Medicine (2019). Medium credibility.

Table 1
Model assumptions regarding the factors affecting the risk of transmission

*Assumption explored in sensitivity analysis

The time to detection of active TB is exponentially distributed, and the associated rate is calculated based on the country's estimated case detection rate (Additional file 1, Section 3.3). Although a detection time is generated for all TB cases, detection only actually occurs if this time precedes the pre-determined time of the natural history outcome.

In our model, all detected cases are commenced on treatment between 0 and 14 days following detection. Successfully treated individuals (i.e. cured or completing treatment) are assumed to clear infection and become susceptible again. If unsuccessfully treated, patients remain active and the TB episode outcome (cure or death) and its timing remain as defined by the TB natural history that was originally generated. Time-variant parameters are used to specify Bacillus Calmette–Guérin (BCG) vaccine coverage, as well as rates of case detection and treatment success. The associated scale-up functions for BCG vaccine coverage and rates of case detection and treatment success are based on WHO data (Additional file 1: Figure S9). The parameters used to inform the model are presented in Table 2.

Table 2
Model parameters

*Parameters included in Latin hypercube sampling; a smear-positive TB; b smear-negative TB; c extrapulmonary TB; d either smear-negative or extrapulmonary TB; e reference: high-intensity contact

In order to understand the role played by the past programmatic conditions in shaping the current epidemic picture, we run an additional analysis where all programmatic parameter values are assumed constant and equal to their most recent estimates.

---

### Potential public health impact of new tuberculosis vaccines [^115FKUkw]. Emerging Infectious Diseases (2004). Low credibility.

Recent sequencing of the M. tuberculosis genome as well as new developments in proteomics and comparative genomics have led to renewed interest in developing new, more effective vaccines against TB. Vaccines currently under development include subunit vaccines, naked DNA vaccines, and attenuated mycobacteria, including recombinant BCGs expressing immunodominant antigens and cytokines. Phase I clinical trials of several of these vaccines are under way or scheduled to begin very soon. TB vaccines under development can be divided into two categories: preexposure or postexposure vaccines. Preexposure vaccines prevent infection and subsequent disease; these vaccines are given to uninfected persons. Postexposure vaccines aim to prevent or reduce progression to disease; these TB vaccines will be given to persons who are already infected with M. tuberculosis. In industrialized countries where TB incidence is low, a preexposure vaccine is the most effective for TB control. However, the most effective type of vaccine to control TB epidemics in high-incidence countries, where prevalence of latent TB infection is high, is not apparent. We use mathematical models to predict the potential public health effect of new TB vaccines for epidemic control in high-incidence countries. We evaluate the effect of both pre- and postexposure TB vaccines on two outcome variables: the number of new infections and the number of new cases of disease. We then discuss health policy implications of our analyses.

---

### Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions [^115r1W3w]. The Lancet: Infectious Diseases (2018). Medium credibility.

Mathematical modelling is commonly used to evaluate infectious disease control policy and is influential in shaping policy and budgets. Mathematical models necessarily make assumptions about disease natural history and, if these assumptions are not valid, the results of these studies can be biased. We did a systematic review of published tuberculosis transmission models to assess the validity of assumptions about progression to active disease after initial infection (PROSPERO ID CRD42016030009). We searched PubMed, Web of Science, Embase, Biosis, and Cochrane Library, and included studies from the earliest available date (Jan 1, 1962) to Aug 31, 2017. We identified 312 studies that met inclusion criteria. Predicted tuberculosis incidence varied widely across studies for each risk factor investigated. For population groups with no individual risk factors, annual incidence varied by several orders of magnitude, and 20-year cumulative incidence ranged from close to 0% to 100%. A substantial proportion of modelled results were inconsistent with empirical evidence: for 10-year cumulative incidence, 40% of modelled results were more than double or less than half the empirical estimates. These results demonstrate substantial disagreement between modelling studies on a central feature of tuberculosis natural history. Greater attention to reproducing known features of epidemiology would strengthen future tuberculosis modelling studies, and readers of modelling studies are recommended to assess how well those studies demonstrate their validity.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^113Pro2o]. Nature Communications (2023). High credibility.

We have demonstrated the potential for calibrated transmission models to be used as a tool for TB burden estimation, and shown it is feasible to calibrate country-level TB models including age and HIV to empirical data while more fully accounting for uncertainty. In doing so, we have developed a number of technical innovations that should be of wider use, especially among those working on TB epidemics in high HIV prevalence settings. We provided a rigorous calculation of the proportion of TB incidence due to recent infection, finding substantial contributions from older infections are compatible with high annual TB infection risks in adults. Interventions that reduce TB transmission have the potential to produce rapid and substantial reductions in incidence in younger age groups, but will need to be combined with improved interventions addressing progression to have a major impact on the burden of TB in these settings.

---

### Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries [^114m3M4Z]. BMC Medicine (2019). Medium credibility.

Background

Tuberculosis (TB) is now the leading cause of death worldwide from a single infectious agent. While effective prevention and treatment tools have been available for many decades, their impact on the global epidemic has been limited by challenges that TB control programs still face today. Among them, the difficulties in identifying diseased individuals and providing them with adequate care may be the most critical, with only 61% of cases receiving effective treatment. Even more alarming is that the global case detection rate could be as low as 35% in children. As well as ensuring that control policies are as effective as possible, comprehensive knowledge of the epidemic age-profile is essential for estimating burden of disease and predicting the course of the epidemic.

TB epidemiology is also clouded by the propensity of Mycobacterium tuberculosis (M.tb) to enter a latent infection state within its host (latent TB infection, LTBI), in which it may persist for many years before reactivating. Source tracing is therefore difficult due to the unknown time lag between infection and activation, making transmission events even more challenging to infer than disease burden. While modelling estimates of the global prevalence of LTBI were recently published, better understanding pathogen transmission in the population and the resulting infection burden would enable better targeting of high-risk groups.

The slow dynamics of TB limit the feasibility of field investigations that could build epidemic knowledge and mean that historical trends for many decades into the past may have significance for the modern epidemic. For these reasons, mathematical modelling provides a valuable tool to investigate hidden features of the disease. In particular, agent-based models, which explicitly simulate each individual in a population, together with their demographic characteristics, social contacts and infection history, capture important heterogeneities present in real-world populations. This faculty is critical when modelling TB, as M.tb transmission is subject to important heterogeneity in characteristics of the infectious host, susceptible host and environment. Meanwhile, the recent availability of contact survey data has dramatically improved our understanding of social mixing. In particular, estimates of age-specific contact frequency and intensity in different contexts/locations are now publicly available and provide empiric evidence of preferential mixing patterns, such as age assortativity. Agent-based models can capture specific patterns of social mixing with a high degree of fidelity. For example, they can account for contact saturation in households and other settings such as schools and workplaces where repeated contact is frequent. Incorporating such contacts into a model can enable more accurate estimates of setting-specific contribution to transmission.

---

### Model-based analysis of impact, costs, and cost-effectiveness of tuberculosis outbreak investigations, United States [^114cecHB]. Emerging Infectious Diseases (2025). Medium credibility.

Table 5
Cost and cost-effectiveness (in 2022 US dollars) of TB outbreak investigation, United States, 2023–2032*

*The point estimate is the mean, and the lower and upper bounds represent the 2.5th and 97.5th percentiles across all 10,000 simulations. LTBI, latent TB infection; QLY, quality-adjusted life-years; TB, tuberculosis. †Future costs of treating future cases are discounted on the basis of their expected time of occurrence up to 5 years into the future.

The factors that were most influential to the estimated cost-effectiveness of outbreak investigation activities consisted of characteristics of outbreak investigations, such as the proportion of contacts that were TB and LTBI cases (Figure 2); epidemiologic quantities, such as the reactivation rate of LTBI cases among outbreak contacts and the number of secondary transmissions per outbreak-related case; and cost-related variables, such as the cost of outbreak investigation (cost per contact) and the cost of treating future TB cases. Under all variations of parameter values evaluated in the sensitivity analysis, the estimated ICER did not exceed $70,000 per additional QALY gained.

Figure 2
Multivariate sensitivity analysis of the model parameters in study of impact, costs, and cost-effectiveness of TB outbreak investigations, United States. This graph illustrates sensitivity of the incremental cost-effectiveness ratio of TB outbreak investigation in the United States (cost in 2022 US$ per QALY gained, compared with no outbreak investigation) to the values of individual model parameters. Each pair of boxplots shows variation in the outcome when the analysis was limited to either simulations in which the value of the parameter of interest was in the top (red) or bottom (blue) decile of its values across all simulations. The edges of each box represent the lower and upper interquartile range, and the band in the middle represents the mean. The vertical dashed line shows the mean across all simulations ($27,800 per QALY gained, corresponding to the primary outcome). The numbers within parentheses represent the parameter range (up to 2 significant figures) for the top (red) or the bottom (blue) decile. IGRA, interferon-γ release assay; LTBI, latent TB infection; QALY, quality-adjusted life-years; R 0, basic reproduction number; TB, tuberculosis.

---

### Estimating the impact of tuberculosis pathways on transmission-what is the gap left by passive case finding? [^115Atpwg]. The Journal of Infectious Diseases (2024). Medium credibility.

With these dynamics, we found that 61.9% (95% UI, 57.7%–65.6%) of individuals who experience infectious disease never become PCF-eligible. When combined with pre-PCF periods of those who do become PCF eligible, half of all transmission occurs before the health system is expected to be accessed, > 80% of which is attributable to subclinical disease. Notably, of the transmission that occurs pre-PCF, just under half occurs within the first 24 months after infection (45.3% [95% UI, 39.7%–51.5%]).

Lowering the threshold for PCF had a limited impact on our findings (Supplementary Figure 3). If PCF eligibility started immediately after the onset of clinical disease, still around half of transmission had already occurred (44.6% [95% UI, 38.7%–50.9%]). These findings were robust to assumptions of relative infectiousness; even when assumed to be 0.25, just under half of transmission occurred during never-PCF-eligible and pre-PCF periods (Supplementary Table 2, Supplementary Figure 4). Conversely, if subclinical disease was assumed to be as infectious as clinical (ie, relative infectiousness was 1.0), only one-third of transmission occurred during PCF-eligible periods (33.5 [95% UI, 28.9%–38.0%]) (Supplementary Table 3, Supplementary Figure 4).

---

### TIME impact-a new user-friendly tuberculosis (TB) model to inform TB policy decisions [^114M9WQY]. BMC Medicine (2016). Low credibility.

Tuberculosis (TB) is the leading cause of death from infectious disease worldwide, predominantly affecting low- and middle-income countries (LMICs), where resources are limited. As such, countries need to be able to choose the most efficient interventions for their respective setting. Mathematical models can be valuable tools to inform rational policy decisions and improve resource allocation, but are often unavailable or inaccessible for LMICs, particularly in TB. We developed TIME Impact, a user-friendly TB model that enables local capacity building and strengthens country-specific policy discussions to inform support funding applications at the (sub-)national level (e.g. Ministry of Finance) or to international donors (e.g. the Global Fund to Fight AIDS, Tuberculosis and Malaria).

TIME Impact is an epidemiological transmission model nested in TIME, a set of TB modelling tools available for free download within the widely-used Spectrum software. The TIME Impact model reflects key aspects of the natural history of TB, with additional structure for HIV/ART, drug resistance, treatment history and age. TIME Impact enables national TB programmes (NTPs) and other TB policymakers to better understand their own TB epidemic, plan their response, apply for funding and evaluate the implementation of the response.

The explicit aim of TIME Impact's user-friendly interface is to enable training of local and international TB experts towards independent use. During application of TIME Impact, close involvement of the NTPs and other local partners also builds critical understanding of the modelling methods, assumptions and limitations inherent to modelling. This is essential to generate broad country-level ownership of the modelling data inputs and results. In turn, it stimulates discussions and a review of the current evidence and assumptions, strengthening the decision-making process in general.

TIME Impact has been effectively applied in a variety of settings. In South Africa, it informed the first South African HIV and TB Investment Cases and successfully leveraged additional resources from the National Treasury at a time of austerity. In Ghana, a long-term TIME model-centred interaction with the NTP provided new insights into the local epidemiology and guided resource allocation decisions to improve impact.

Electronic supplementary material

The online version of this article (doi:10.1186/s12916-016-0608-4) contains supplementary material, which is available to authorized users.

---

### Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study [^112aJXWc]. The Lancet: Global Health (2019). High credibility.

Background

Tuberculosis is the leading single-pathogen cause of death worldwide, and China has the third largest number of cases worldwide. New tools, such as new vaccines, are needed to meet WHO tuberculosis goals. Tuberculosis vaccine development strategies mostly target infants or adolescents, but given China's ageing epidemic, vaccinating older people might be important. We modelled the potential impact of new tuberculosis vaccines in China targeting adolescents (15–19 years) or older adults (60–64 years) with varying vaccine characteristics to inform strategic vaccine development.

Methods

A Mycobacterium tuberculosis transmission model was calibrated to age-stratified demographic and epidemiological data from China. Varying scenarios of vaccine implementation (age targeting [adolescents or older adults] and coverage [30% or 70%]) and characteristics (efficacy [40%, 60%, or 80%], duration of protection [10 years or 20 years], and host infection status required for efficacy [pre-infection, post-infection in latency, post-infection in latency or recovered, or pre-infection and post-infection]) were assessed. Primary outcomes were tuberculosis incidence and mortality rate reduction in 2050 in each vaccine scenario compared with the baseline (no new vaccine) scenario and cumulative number needed to vaccinate (NNV) per case or death averted, 2025–50.

Findings

By 2050, results suggest that 74.5% (uncertainty interval [UI] 70.2–78.6) of incident tuberculosis cases in China would occur in people aged 65 years or older, and 75.1% (66.8–80.7) of all cases would be due to reactivation, rather than new infection. All vaccine profiles delivered to older adults had higher population-level impact (reduction of incidence and mortality rates) and lower NNV per case and per death averted than if delivered to adolescents. For an intermediate vaccine scenario of 60% efficacy, 10-year protection, and 70% coverage, the reduction of tuberculosis incidence rates with older adult vaccination was 1.9 times (UI 1.5–2.6) to 157.5 times (119.3–225.6) greater than with adolescent vaccination, and the NNV was 0.011 times (0.008–0.014) to 0.796 times (0.632–0.970) lower. Furthermore, with older adult vaccination, post-infection vaccines provided substantially greater mortality and incidence rate reductions than pre-infection vaccines.

Interpretation

Adolescent-targeted tuberculosis vaccines, the focus of many development plans, would have only a small impact in ageing, reactivation-driven epidemics such as those in China. Instead, an efficacious post-infection vaccine delivered to older adults will be crucial to maximise population-level impact in this setting and would provide an important contribution towards achieving WHO goals. Older adults should be included in tuberculosis vaccine clinical development and implementation planning.

Funding

Aeras and UK MRC.

---

### The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis [^111DnaSk]. EClinicalMedicine (2020). Medium credibility.

Introduction

The emergence of the novel virus SARS-CoV-2 has caused morbidity, mortality and societal disruption on a global scale. In the absence of pharmaceutical interventions, many countries have resorted to population-wide lockdowns to slow the spread of the virus and to allow their health systems to cope. These lockdowns have had an important effect on SARS-CoV-2 transmission. However, unintended consequences are inevitable with such sweeping measures. In low- and middle-income countries with health systems already under strain, the adverse effects of disruptions in health services (for example, ongoing transmission of infectious diseases) can last far beyond the period of the disruptions themselves.

In the present study we focus on tuberculosis (TB) - globally, the leading cause of death due to an infectious disease. In recent decades TB incidence and mortality have been steadily declining, reflecting ongoing improvements in diagnosis, treatment and prevention. However, in March 2020 a rapid analysis conducted by the Stop TB Partnership brought attention to severe impacts of COVID-related lockdowns on TB care in different countries. For example, in the weeks following the imposition of a nationwide lockdown on March 24, 2020, India reported an 80% drop in daily notifications of TBrelative to average pre-lockdown levels. Similar changes have been reported elsewhere, for example with South Africa reporting a drop in numbers tested for TB by almost a half. Such declines may be partly due to delays in reporting but are also likely to reflect reductions in access to diagnosis and treatment, potentially having a lasting impact on TB burden at a country-wide level. Missed diagnoses would mean increased opportunities for transmission, while worsened treatment outcomes increase the risk of death from TB. Therefore, while lockdowns are an important measure to mitigate the immediate impact of COVID-19, it is critical to anticipate (i) the potential long-term impact of these measures on TB and other diseases, and (ii) how this impact might be stemmed, in the short term, by appropriately targeted investment and effort. We therefore aimed to examine these questions using mathematical modelling of TB transmission dynamics. Building on earlier modelling conducted for the 2019 Lancet Commission on Tuberculosis, we modelled the potential TB-related impact of COVID-related lockdowns - and mitigating effects of potential post-lockdown interventions - in three focal countries: India, the Republic of Kenya, and Ukraine. It is not possible to predict the extent or depth of lockdowns in any given country, let alone their impact on TB services. Therefore, the primary purpose of our analysis is not to predict future TB trajectories, but rather to identify the critical drivers through which a lockdown can lead to elevated TB incidence and mortality, and to apply these insights to understand how best mitigate the long-term adverse impact of any lockdown-related disruptions.

---

### Potential public health impact of new tuberculosis vaccines [^114tqh86]. Emerging Infectious Diseases (2004). Low credibility.

Also, the increasing HIV epidemic will lead to continuous increases in the incidence of TB in developing countries. Currently, what effect co-infection with HIV will have on TB vaccine effectiveness is unclear; possibly, HIV co-infection could reduce vaccine effectiveness. Thus, any new TB vaccine should be evaluated in clinical trials to determine the effect of HIV coinfection on vaccine effectiveness. To reduce the severity of TB epidemics, we recommend that developing and deploying vaccines that act as both pre- and postexposure vaccines are necessary to simultaneously attack both sources that drive the TB rate. Additionally, maintaining high rates of detection and treatment of tuberculosis is necessary, as recommended by the World Health Organization; by combining treatment and vaccination strategies, eradicating TB epidemics may be possible, as we have previously shown.

Our results have implications for designing both TB vaccines and vaccination campaigns. Highly effective vaccines will be needed to have the public health impact that we have shown (i.e. to reduce the TB death rate by one third). Whether or not the vaccines currently in development will afford this level of efficacy remains to be seen. Moreover, vaccines will need to provide very long-lasting immunity; our current analysis examines the effect of fairly long-lasting vaccines (10–30 years average duration of immunity). Different types of vaccines have different durations of immunity. For example, DNA vaccines should provide lifelong immunity, whereas subunit vaccines will likely require booster vaccinations, an approach that would be more logistically difficult and expensive. Also, we have shown that preexposure vaccines are best if they prevent infection (mechanism 1) rather than allow infection but reduce the probability of fast progression to disease (mechanism 2) or reduce the rate of progression of latently infections to disease (mechanism 3). Whether or not new TB vaccines will prevent infection from occurring is not known, but BCG is clearly not able to prevent infection, and vaccines currently in development will likely not be able to do so either. As new TB vaccines and other control strategies become available, their potential benefits to TB control efforts can be evaluated by mathematical modeling. Mathematical models can be used as health policy tools to evaluate strategies for controlling TB; mathematical models also provide insights for predicting the potential public health impact of imperfect HIV vaccines. Our results show that, because of the complex pathogenic process of TB, high-incidence epidemics are unlikely to be substantially reduced by widely deploying highly effective preexposure or postexposure vaccines. We suggest that to achieve global control of TB, developing a single TB vaccine that functions as both a pre- and a postexposure vaccine is necessary.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^111GKYSu]. Nature Communications (2023). High credibility.

Tuberculosis (TB) killed more people globally than any other single pathogen over the past decade. Where surveillance is weak, estimating TB burden estimates uses modeling. In many African countries, increases in HIV prevalence and antiretroviral therapy have driven dynamic TB epidemics, complicating estimation of burden, trends, and potential intervention impact. We therefore develop a novel age-structured TB transmission model incorporating evolving demographic, HIV and antiretroviral therapy effects, and calibrate to TB prevalence and notification data from 12 African countries. We use Bayesian methods to include uncertainty for all TB model parameters, and estimate age-specific annual risks of TB infection, finding up to 16.0%/year in adults, and the proportion of TB incidence from recent (re)infection, finding a mean across countries of 34%. Rapid reduction of the unacceptably high burden of TB in high HIV prevalence settings will require interventions addressing progression as well as transmission.

---

### Estimating the population at high risk for tuberculosis through household exposure in high-incidence countries: a model-based analysis [^114n6vYg]. EClinicalMedicine (2021). Medium credibility.

1 Introduction

Nearly 10 million people develop tuberculosis (TB) each year despite decades of research and public health effort to prevent this bacterial infection. Global rates of new TB illness are not declining rapidly enough to reach international morbidity and mortality targets, such as the Sustainable Development Goals Target 3.3 and the Stop TB Partnership target for TB incidence. Effective TB prevention efforts include evaluating persons who are at elevated risk for TB due to sharing a household with someone with active TB, which is primarily acquired via inhalation of bacteria that become aerosolized from the respiratory system of a person with pulmonary TB. Providing courses of anti-tuberculous medications as TB preventive treatment (TPT) reduces the risk of developing active TB among household contacts without signs or symptoms of active TB at the time of screening.

Recently, the World Health Organization (WHO) offered a conditional recommendation to broaden the age range of household contacts in countries with high TB incidence who may receive TPT. Historically, children under the age of 5 years living in the household of a person with pulmonary TB have been prioritized due to their greater risk for developing TB disease than older children or adults. The guidelines updated in 2018 and 2020 expanded the eligible population of household contacts to include children older than 5 years, adolescents, and adults in countries with high TB incidence in the context of clinical assessment of likely benefits and risks and in the context of local TB epidemiology. The UN High-Level Meeting on TB in 2018 achieved a commitment to provide TPT to 20 million persons over age 5 by 2022, though fewer than 1 million household contacts age 5 or older received TPT in 2018 and 2019.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^115VyYqn]. Nature Communications (2023). High credibility.

Results

Below, we present fits of our simplified TB transmission model (see Fig. 1) to available demographic and epidemiological data, and our inferred estimates of national-level TB incidence and mortality, the proportion of TB incidence in PLHIV, the proportion of TB incidence due to infection within the last two years, and also TB infection risks and age-specific contributions to transmission.

Fig. 1
Process flow and model diagram.

Blue lines for the TB transmission model in step 4 are processes to which HIV/ART-associated incidence rate ratios IRR(t, s, a, ART) are applied. These time-dependent IRRs (step 2) capture the implications of the AIM model of HIV/ART progression (step 1) for TB risk for each aggregated age, sex, and HIV/ART stratum in the simplified transmission model (step 4). The influence of ART-protection and CD4 risk dependence parameters on simplified transmission model dynamics (step 4) is achieved by emulating the dependence of IRR trajectories on these model parameters (step 3), allowing them to be included in inference (step 5). Red boxes in step 4 represent calibration targets.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^1145xhi9]. Nature Communications (2023). High credibility.

Discussion

By calibrating a transmission model of TB on an evolving background of demography and HIV-related immunocompetence, we have been able to reproduce patterns in empirical TB data and provide a new method for estimating TB burden in settings with TB prevalence surveys and generalized HIV epidemics. Previous approaches to modelling national-level TB epidemics have had to use existing burden estimates as calibration targets and severely limit the number of model parameters treated as uncertain. Our key innovation is to fit an age-structured TB transmission model to empirical data in a fully-Bayesian framework, generating independent epidemiological and burden estimates while reflecting parametric uncertainty. Important new findings arising from this approach include elucidation of strongly age-dependent proportions of TB incidence from infection within the last two years, and that while TB incidence and mortality have declined in the ART era, TB incidence remains enduringly high with nearly half of TB incidence in these countries among people living with HIV, despite rapid scale-up of ART. These findings suggest that, as ART programmes reach high coverage in many African countries, renewed focus on tuberculosis detection, care and prevention in PLHIV (as well as among HIV-negative people) will be required to accelerate progress towards elimination. Potential approaches include expansion of regular, routine TB screening for people attending HIV care clinics (e.g. annual chest X-ray screening), implementation and expansion of shorter, more tolerable TB preventive therapies, and action to tackle the social determinants and consequences of TB.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^114YuYg3]. Nature Communications (2023). High credibility.

Introduction

Over the past decade, tuberculosis (TB) has killed more people than any other pathogen, averaging more than 1.65 million deaths per year between 2010–2019, of which > 363,000 deaths per year were among people living with HIV (PLHIV). HIV infection has a large impact on TB in individuals: risks of developing TB increase steeply as CD4 cell counts decline, as does the likelihood of death among those not receiving treatment for TB. Antiretroviral therapy (ART) for PLHIV increases life-expectancy, and reduces TB mortalityand incidence(although not to the level of HIV-uninfected people). This has led to dynamic TB epidemics in settings with generalized HIV epidemics, with rapid increases in TB notifications driven by declines in mean CD4 cell counts among people living with HIV (PLHIV), followed by declines in TB notifications as ART coverage has increased. Globally in 2020, 8% of TB incidence and 14% of all TB deaths occurred among PLHIV. In the World Health Organization (WHO) African region, these figures are 24% and 31%, respectively; 22 out of the 30 WHO high TB/HIV countries are in Africa.

Our understanding of the global epidemiology of TB is based on estimates of disease incidence and mortality, notably those generated annually by WHO. In many countries with high TB incidence, the gap between estimated TB incidence and cases detected and reported as starting anti-TB treatment (notifications) is substantial, complicating surveillance and accurate measurement of epidemic trajectories. WHO has supported nationally-representative TB prevalence surveys in priority countries, as these provide a measure of TB burden that is less subject to bias than notification data –. Since 1990, 43 national TB prevalence surveys have been undertaken and reported results, including 16 in Africa. The large sample sizes required mean TB prevalence surveys are expensive to execute, and they are typically powered to generate a relative precision of only + /− 20%.

Combining data from prevalence surveys with notifications data (and potentially vital registration data) to produce estimates of incidence and mortality in high HIV-prevalence settings requires a framework that can incorporate the evolving relationship between incidence, prevalence, and mortality, the effects of HIV, and which can formally account for the uncertainty and relative informativeness inherent in each source of data. Current approaches to TB/HIV burden estimation use dichotomized states to represent HIV and ART which do not capture their evolving and context-specific relationship with TB risk.

---

### Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines [^115R4XEa]. Nature Communications (2023). High credibility.

In tuberculosis (TB) vaccine development, multiple factors hinder the design and interpretation of the clinical trials used to estimate vaccine efficacy. The complex transmission chain of TB includes multiple routes to disease, making it hard to link the vaccine efficacy observed in a trial to specific protective mechanisms. Here, we present a Bayesian framework to evaluate the compatibility of different vaccine descriptions with clinical trial outcomes, unlocking impact forecasting from vaccines whose specific mechanisms of action are unknown. Applying our method to the analysis of the M72/AS01 E vaccine trial -conducted on IGRA+ individuals- as a case study, we found that most plausible models for this vaccine needed to include protection against, at least, two over the three possible routes to active TB classically considered in the literature: namely, primary TB, latent TB reactivation and TB upon re-infection. Gathering new data regarding the impact of TB vaccines in various epidemiological settings would be instrumental to improve our model estimates of the underlying mechanisms.

---

### Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries [^113TPcVS]. BMC Medicine (2019). Medium credibility.

Conclusions

We show that it is possible to create new and valuable insights into the profile of local TB epidemics by combining agent-based simulation with social mixing data and TB control history. We demonstrate that social contacts involving 15–19-year-old individuals are a critical driver of TB which is not evident from the age distribution of TB cases. Our model also highlights the high burden of childhood TB in high-incidence settings and underlines the critical role played by parents-to-children transmission.

---

### Achieving a "step change" in the tuberculosis epidemic through comprehensive community-wide intervention: a model-based analysis [^113DL8ea]. BMC Medicine (2021). Medium credibility.

We made several modeling choices to represent the natural history of TB, in which data are either sparse or open to multiple interpretations. (i) We assumed that TB infection imparts partial immunity to reinfection (because individuals with evidence of LTBI are less likely to develop TB disease after reexposure) and that this immune protection extends to those who were previously treated (for both LTBI and TB disease) or those who spontaneously resolved. The inclusion of protection for those who had received treatment is consistent with other TB modeling literature, and has little impact on our main results, but it means that our model relies solely on relapse and geographic risk heterogeneity to account for the higher risk of recurrence faced after treatment for TB disease. (ii) Relatedly, we modeled the rate of late progression of LTBI to be non-zero; recent analyses have argued that remote infections rarely progress after a few years or may even become sterilized without antitubercular therapy. The true risk of progression among individuals with remote TB infection remains poorly understood but can be consequential for the impact of these interventions. In our simulations, we found that the impact in terms of cases averted was about 30% larger in simulations where the rates of late progression were in the top decile, compared to the bottom decile (Additional File 1 :Fig. S-2). In addition, if preventive therapy could be targeted to individuals with recent infection (e.g. if diagnostic assays for recent infection could be developed), up to 89% of cumulative 10-year TB mortality could be averted, while only delivering preventive therapy to one-tenth of the infected population (Additional File 1 :S-6). Furthermore, if the reactivation rates of remote TB reactivation (and consequently the lifetime benefits of TPT) are substantially lower, it will be important to carefully weigh the risks and benefits of TPT. Prioritizing populations based on risks, such as household contacts of known TB cases and those with underlying risk factors, may be necessary. (iii) Finally, our model included the potential for TB disease to resolve without treatment (via regression and spontaneous resolution); the estimated rates of regression and resolution varied over a wide range in our calibrated models, reflecting not just uncertainties in these estimates but also a correlation with other parameters (e.g. late progression rates). Rates of resolution in the bottom decile, which were closer to estimates in a recent study, yielded estimates of cases averted that were up to 15% smaller than the median estimate (Additional File 1 :Fig. S-2). However, the estimated number of deaths averted was more robust to these parameter choices (Fig. 6).

---

### Transmissibility and potential for disease progression of drug resistant: prospective cohort study [^113o1ajx]. BMJ (2019). Excellent credibility.

Conclusion and policy implications

The results of our study have major implications for public health policy and for measuring the burden of drug resistant tuberculosis. Mathematical models suggest that the expected trajectories of drug sensitive tuberculosis and drug resistant tuberculosis strongly depend on the fitness cost of clinically relevant resistance mutations. If M tuberculosis drug resistance exacts no fitness cost, the incidence of drug resistant and multidrug resistant tuberculosis will be expected to fall more slowly than would be expected; this prediction would apply even in populations where the acquisition of new drug resistance is minimized through measures such as supervised treatment to ensure adherence to standardized empirical regimens. Our findings provide evidence that invites guideline producers to take action by targeting drug resistant tuberculosis and multidrug resistant tuberculosis, such as the early detection and effective treatment of infection and disease. These guidelines should include the wider deployment of existing tools and the development of diagnostic and therapeutic strategies designed specifically for people already infected with drug resistant tuberculosis.

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^112d1Pdc]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Tuberculosis (TB) is the leading global cause of infectious disease deaths. For a small fraction of those infected with Mycobacterium tuberculosis (Mtb), active disease develops rapidly after exposure. For the rest, latent TB infection (LTBI) confers an ongoing risk of TB, such that exposures early in life can result in active disease many years later. TB in the United States arises predominantly among non–U.S.-born individuals, and although annual TB cases among U.S.-born individuals have been declining steadily, annual TB cases among non–U.S.-born individuals have stabilized at 6,200–6,400 since 2012. Future projections of U.S. TB incidence suggest stagnation of historical rates of decline and an increasing fraction of cases arising among the non–U.S.-born population. Mtb exposure within the United States is low, and most TB cases in non–U.S.-born residents are attributed to reactivation of long-standing LTBI, which was likely acquired before entry to the United States. U.S. TB policy and services are centered on LTBI testing and treatment for non–U.S.-born residents and other high-risk populations, with these epidemiological dynamics and accompanying control strategies mirroring those in other low-burden, high-income countries.

TB incidence trends in migrants' birth countries determine their cumulative Mtb exposure before entry, which in turn will determine the risks of TB from LTBI reactivation they face after entry. Mathematical modeling has demonstrated the sensitivity of U.S. TB epidemiology to TB trends among migrants, and the potential benefits to the United States of better TB control in selected countries, raising the question of whether TB treatment and prevention in countries contributing most to the U.S. TB burden should be considered in parallel to massive efforts to test and treat migrants for LTBI after U.S. arrival.

This study describes how future TB outcomes in the United States — where one in seven residents is born abroad — will be influenced by the success or failure of TB control in migrants' birth countries. In this study, we compare a base-case scenario — assuming current TB incidence trends continue — with an optimistic scenario in which birth countries (individually or collectively) achieve 90% TB incidence reductions between 2015 and 2035, as envisioned by the World Health Organization (WHO) End TB Strategy. We also examine a pessimistic scenario wherein TB incidence rates in birth countries remain at current levels.

---

### Economic analyses to inform public health decision-making for tuberculosis: the role of understanding implementation [^115aNVQG]. BMC Medicine (2019). Medium credibility.

Background

Tuberculosis (TB) kills more people than any other infectious disease in the world today. The global public health response is rising accordingly. To address the considerable gaps in TB management in high-burden countries, there is increasing pressure for health systems to rapidly and effectively implement innovations in TB diagnosis and treatment. High-level policy guidance, such as the World Health Organization's End TB Strategy, the Sustainable Development Goals (SDG), and the United Nation's (UN's) High Level Meeting in 2018 all call for novel strategies to optimize the impact of these interventions. Modeling analyses, such as that recently published by Sohn and colleagues in BMC Medicine, are becoming increasingly instrumental in guiding policy decisions.

However, in most high-burden settings, it remains unknown how best to operationalize and scale up interventions, at a sustainable cost – critical concerns of stakeholders and decision-makers. Research exists, but it makes for poor generalizations. Delivery models for effective implementation of TB diagnosis and treatment innovations are often context-specific – influenced by local conditions in health system capacity and demand for services. Effectiveness is often narrowly or inconsistently defined. Together, these limitations greatly reduce the utility of cost-effectiveness and budgetary impact analyses, which are intended to inform the choices that programs must make about how to scale up novel technologies to maximize public health benefit.

---

### Model-based analysis of impact, costs, and cost-effectiveness of tuberculosis outbreak investigations, United States [^113JDaEo]. Emerging Infectious Diseases (2025). Medium credibility.

Methods

Projection of TB Outbreaks in the United States

We projected the number of TB cases, the number of TB clusters, and the distribution of cluster sizes in the United States during 2023–2032. TB cases were projected by extrapolating the trend of TB cases during 2014–2019 (1.1% annual decline). To allow for additional uncertainty in TB incidence caused by other factors, such as the COVID-19 pandemic–related disruptions, we assumed that, relative to the prepandemic TB trajectory, from a 5% increase to a 10% decline could be seen in the number of cases projected during the study period (Tables 1, 2). We simulated cluster size distributions of TB outbreaks using a branching process model with a Poisson lognormal distribution. This model was previously developed and fitted to genotype cluster size distribution data in the United States, where cases were defined as clustered if they had matching spacer oligonucleotide typing (spoligotype) and 24-locus mycobacterial interspersed repetitive unit–variable number tandem-repeat genotyping results, and they were reported within the same state during 2012–2016 (Appendix). Finally, we estimated the number of clusters on the basis of both the projected number of incident cases and the cluster size distribution, such that the sum of cases across simulated clusters equaled the projected number of incident cases.

Table 1
Descriptions, estimates and uncertainty ranges for parameters describing TB outbreaks and outbreak investigations in study of impact, costs, and cost-effectiveness of TB outbreak investigations, United States*

*3HP, 3 months of isoniazid and rifapentine; 9H, 9 months of isoniazid; ARPE, Aggregate Reports for Program Evaluation; CDC, Centers for Disease Control and Prevention; IGRA, interferon-γ release assay; LTBI, latent TB infection; QALY, quality-adjusted life-years; R 0, basic reproduction number; TB, tuberculosis. †Based on Poisson lognormal distributions fitted to cluster-size distribution of genotype linked cases in the United States during 2012–2016.

Table 2
Descriptions, estimates and uncertainty ranges for parameters describing TB natural history, costs of TB outbreak investigations, and cost-effectiveness evaluation in study of impact, costs, and cost-effectiveness of TB outbreak investigations, United States*

---

### American Thoracic Society / centers for disease control and prevention / Infectious Diseases Society of America: controlling tuberculosis in the United States [^115b1AYF]. American Journal of Respiratory and Critical Care Medicine (2005). Medium credibility.

Tuberculosis research priorities — progress toward elimination: A comprehensive TB research plan for the United States should be developed that identifies the major areas of need and the most effective research approaches to meet those needs, and CDC and NIH should convene a broad based group of experts and stakeholders to develop this plan (AIII). The availability of improved diagnostic tests and therapies for LTBI would have an immediate and lasting impact on the incidence of TB in the United States, and research on those fields should be a priority (AIII). Research leading to a new and effective TB vaccine is one of the most important contributions that the United States can make to the global TB epidemic and should be a priority (AIII). The CDC-funded Tuberculosis Epidemiological Studies Consortium and Tuberculosis Trials Consortium represent excellent new models for bringing resources together to plan and implement research for the assessment of new diagnostics and drugs and epidemiologic and operational research on TB, and these initiatives should be a priority (AIII). Because a substantial number of recommendations for TB control are based on logic, anecdotal experience, and expert opinion, additional research, including clinical, operational, behavioral, and economic research should focus on unanswered questions relating to the basic elements of TB control (AIII).

---

### Evaluation of the use of modelling in resource allocation decisions for HIV and TB [^115bRRcH]. BMJ Global Health (2024). High credibility.

Introduction

Although countries have made critical gains in reaching global targets towards HIV and tuberculosis (TB) elimination, closing the remaining gap in prevention and treatment targets will require strategic investment. As international HIV investment becomes increasingly constrained, countries are shifting to internal resources to fund their HIV responses. In low-income and middle-income countries, the domestic share of HIV funding has increased from 51% in 2010 to 61% in 2020, and global funds available for HIV have been decreasing since 2017. Similarly for TB, financing gaps to meet end-TB targets have widened since 2016, particularly among low-income and middle-income countries. Shrinking budget envelopes mean that governments need to make challenging decisions on HIV and TB investments amidst competing health and social priorities.

Mathematical modelling has been widely used to project epidemics at national and global levels, with models such as the Spectrum suite used to produce HIV epidemiological estimates to guide national policy and planning. Mathematical modelling is also recognised as an important tool when there are gaps in empirical data, or to compare the potential impact of different intervention, policy or funding scenarios. The use of mathematical modelling to guide health policy decisions for infectious diseases has burgeoned in recent years. As well as projecting epidemics under different intervention scenarios, some models can be used to inform financial resource allocation.

Optima HIV and TB are dynamic, compartmental population-based models of disease transmission and progression for HIV and TB, respectively, integrated with an economic and programme analysis framework to assess allocative efficiency. The models apply a mathematical algorithm to estimate the most cost-effective allocation of resources across disease-specific interventions to maximise progress towards specific objectives, such as reduction of new HIV-infections and HIV-related deaths or country-defined targets. The models estimate the projected impact of different funding allocations on epidemic outcomes in comparison to outcomes if current spending patterns were maintained. The underlying epidemiology in each model application is calibrated to align with official reported estimates where they are available, such as those produced through Spectrum, and model outputs are validated with in-country stakeholders. Analyses are completed in partnership with national stakeholders from Ministries of Health and national disease programmes and coordinating or funding agencies. The technical modelling team provides training of varying intensity to partnering stakeholders on using and interpreting the Optima models. Optima HIV and TB models have been applied in over 50 countries since 2010 and 2016, respectively, in collaboration with the World Bank, international and country partners. However, it has not yet been qualitatively evaluated how these models have influenced policy or financing.

---

### Use of modeling to inform tuberculosis elimination strategies [^1112EBJN]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Although the United States reported its lowest number of tuberculosis (TB) diagnoses in 2018 (2.8 cases per 100,000 persons), the decline in TB incidence has slowed in recent years and the current pace of this decline is too slow to reach the national goal of TB elimination (defined as an annual incidence of less than one case per 1 million population) within this century.

In a study presented in this issue of the Journal, Menzies and colleagues (pp.) compared three epidemiologic models to analyze the potential impact of different interventions in California, where 82.6% of individuals with TB in 2018 were born outside of the United States. Although the authors credit the successful implementation of TB control principles (e.g. early detection of active TB disease and prompt initiation and completion of appropriate therapy) for reducing TB incidence to historic lows in the United States, all three models show that in the absence of additional interventions, these activities alone will not be enough to significantly reduce TB incidence in the United States in the coming decades.

The authors provide a thoughtful and nuanced discussion about the role and utility of modeling, and their use of multiple modeling methodologies in this study helps to strengthen the impact of results that are concordant across the models. However, the authors also note the inherent limitations of these models in the absence of more robust data. Such an approach can also help individuals involved in TB control programs and policy makers better understand the implications and potential applications of these findings within their own local context.

Across the models used in this analysis, recent transmission accounted for a small proportion of overall TB morbidity in California, and a scenario involving halting of future TB transmission led to a predicted reduction between 8.1% and 25.5% in new TB cases. For jurisdictions where TB incidence rates are elevated and TB outbreaks still occur (e.g. New York and Seattle), efforts to identify and interrupt TB transmission through contact investigations, outbreak detection and response, and community-based interventions that address barriers to diagnosis and preventive treatment remain a priority. However, as these models and others demonstrate, addressing domestic TB transmission alone will not negate the need for other strategies, and additional actions to address the community burden of latent TB infection (LTBI) are required to accelerate the pace of TB decline.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^1127LfnV]. Nature Communications (2023). High credibility.

Models of TB transmission calibrated to empirical data provide a potential alternative approach to estimating global, regional and national TB burden, but have not been used to date due to technical challenges including the complexity of TB models (especially TB/HIV models), the large number of uncertain parameters, and limitations in surveillance data. Due to slow timescales in TB progression, models need to be run over timescales representing decades, and evolving age-structures are likely to be important determinants of TB trends. HIV is strongly patterned by age and sex, and evolving population CD4 cell count distributions among PLHIV and increasing ART coverage result in a dynamic relationship between HIV and TB increasing the model complexity. Many of the parameters describing the natural history of TB are imprecisely known due to long timescales, rareness of measurable outcomes, and suboptimal diagnostic accuracy.

Calibrating transmission models to data also provides a way to estimate important, transmission-specific epidemiological metrics that are difficult or impossible to measure directly. Patterns by age of infection risk or contribution to the force-of-infection can identify age groups for efficiently targeted interventions to reduce either exposure risks or prevalent disease that is driving transmission. For example, if in a particular country working-age, people contributed a disproportionately large force-of-infection, then a public health strategy of targeted community screening for this group might be an efficient approach to rapidly reduce the incidence of infection — and hence disease — for adults and children. The proportion of TB incidence due to infection or re-infection within a given period is important for projecting trends, and because it quantifies the extent to which interventions can generate indirect benefits through reduced TB incidence, it influences the best choice or design of intervention.

Here we present a novel transmission model/calibration framework that incorporates the dynamic complexity of HIV-fueled TB epidemics and demographic change. We are able to calibrate this model to surveillance data in a likelihood-based formal Bayesian approach with all parameters considered as uncertain. In applying this framework to the 12 WHO high TB/HIV countries in Africa with a nationally representative TB prevalence survey, we provide a new approach to estimating TB burden over time in these settings, and estimate new age-specific metrics of transmission.

---

### Herd immunity, vaccination and moral obligation [^116GbXAM]. Journal of Medical Ethics (2023). Medium credibility.

Third, the percentage of immune individuals being above the HIT will suppress R below 1 under certain conditions. R0, from which the HIT is calculated, is a descriptive statistic derived from observations of the early phases of specific real world epidemics. Although it is often (arguably incorrectly) described as a property of the pathogen, it is impossible to isolate the transmissibility of a microbe from the context of its hosts and environment (ie, the contexts in which real world epidemics occur). The observed R0 for any given pathogen thus varies in different populations, different methods for deriving R0 produce widely divergent values, and transmission patterns may vary over time.

Standard HITs are derived from simplistic infectious disease models that assume, for example, random mixing (each person in a population is equally likely to have contact with another person) and the absence of seasonality. However, the percentage of immune individuals required to suppress R below 1 will be inaccurately estimated by such models insofar as infections cluster together (mixing is non-random) or environmental and behavioural changes take place in winter (seasonal changes affect transmission); either of these factors, among others, can cause an unaccounted-for increase in transmission.

Fourth, it would be a mistake to conflate reaching the HIT with elimination. Even if we assume the basic account above holds, reaching the HIT is not the point at which elimination occurs and infections disappear. Just above the threshold, R is slightly below 1. This means that an infected person will, on average, transmit infection to slightly less than one other person. In most epidemics in sizeable populations a large number of cases (thus often considerable harm) will continue to occur after R reaches 0.99, even if it is maintained below 1, although fewer cases will occur over time. Moreover, the progression from reaching the HIT to elimination is not guaranteed and may in some cases be hindered by factors including waning immunity, altered patterns of contact in the population and (re)introduction of (new) strains of the pathogen.

---

### Global, regional, and national burden of tuberculosis, 1990–2016: results from the global burden of diseases, injuries, and risk factors 2016 study [^111rQvYk]. The Lancet: Infectious Diseases (2018). Medium credibility.

Background

Although a preventable and treatable disease, tuberculosis causes more than a million deaths each year. As countries work towards achieving the Sustainable Development Goal (SDG) target to end the tuberculosis epidemic by 2030, robust assessments of the levels and trends of the burden of tuberculosis are crucial to inform policy and programme decision making. We assessed the levels and trends in the fatal and non-fatal burden of tuberculosis by drug resistance and HIV status for 195 countries and territories from 1990 to 2016.

Methods

We analysed 15943 site-years of vital registration data, 1710 site-years of verbal autopsy data, 764 site-years of sample-based vital registration data, and 361 site-years of mortality surveillance data to estimate mortality due to tuberculosis using the Cause of Death Ensemble model. We analysed all available data sources, including annual case notifications, prevalence surveys, population-based tuberculin surveys, and estimated tuberculosis cause-specific mortality to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how the burden of tuberculosis differed from the burden predicted by the Socio-demographic Index (SDI), a composite indicator of income per capita, average years of schooling, and total fertility rate.

Findings

Globally in 2016, among HIV-negative individuals, the number of incident cases of tuberculosis was 9.02 million (95% uncertainty interval [UI] 8.05–10.16) and the number of tuberculosis deaths was 1.21 million (1.16–1.27). Among HIV-positive individuals, the number of incident cases was 1.40 million (1.01–1.89) and the number of tuberculosis deaths was 0.24 million (0.16–0.31). Globally, among HIV-negative individuals the age-standardised incidence of tuberculosis decreased annually at a slower rate (-1.3% [-1.5 to -1.2]) than mortality did (-4.5% [-5.0 to -4.1]) from 2006 to 2016. Among HIV-positive individuals during the same period, the rate of change in annualised age-standardised incidence was -4.0% (-4.5 to -3.7) and mortality was -8.9% (-9.5 to -8.4). Several regions had higher rates of age-standardised incidence and mortality than expected on the basis of their SDI levels in 2016. For drug-susceptible tuberculosis, the highest observed-to-expected ratios were in southern sub-Saharan Africa (13.7 for incidence and 14.9 for mortality), and the lowest ratios were in high-income North America (0.4 for incidence) and Oceania (0.3 for mortality). For multidrug-resistant tuberculosis, eastern Europe had the highest observed-to-expected ratios (67.3 for incidence and 73.0 for mortality), and high-income North America had the lowest ratios (0.4 for incidence and 0.5 for mortality).

Interpretation

If current trends in tuberculosis incidence continue, few countries are likely to meet the SDG target to end the tuberculosis epidemic by 2030. Progress needs to be accelerated by improving the quality of and access to tuberculosis diagnosis and care, by developing new tools, scaling up interventions to prevent risk factors for tuberculosis, and integrating control programmes for tuberculosis and HIV.

Funding

Bill & Melinda Gates Foundation.

---

### Quantifying the global number of tuberculosis survivors: a modelling study [^1148JhK4]. The Lancet: Infectious Diseases (2021). High credibility.

Background

People who survive tuberculosis face clinical and societal consequences after recovery, including increased risks of recurrent tuberculosis, premature death, reduced lung function, and ongoing stigma. To describe the size of this issue, we aimed to estimate the number of individuals who developed first-episode tuberculosis between 1980 and 2019, the number who survived to 2020, and the number who have been treated within the past 5 years or 2 years.

Methods

In this modelling study, we estimated the number of people who survived treated tuberculosis using country-level WHO data on tuberculosis case notifications, excluding those who died during treatment. We estimated the number of individuals surviving untreated tuberculosis using the difference between WHO country-level incidence estimates and notifications, applying published age-stratified and HIV-stratified case fatality ratios. To estimate survival with time, post-tuberculosis life tables were developed for each country-year by use of UN World Population Prospects 2019 mortality rates and published post-tuberculosis mortality hazard ratios.

Findings

Between 1980 and 2019, we estimate that 363 million people (95% uncertainty interval [UI] 287 million-438 million) developed tuberculosis, of whom 172 million (169 million-174 million) were treated. Individuals who developed tuberculosis between 1980 and 2019 had lived 3480 million life-years (95% UI 3040 million-3920 million) after tuberculosis by 2020, with survivors younger than 15 years at the time of tuberculosis development contributing 12% (95% UI 7–17) of these life-years. We estimate that 155 million tuberculosis survivors (95% UI 138 million-171 million) were alive in 2020, the largest proportion (47% [37–57]) of whom were in the WHO South-East Asia region. Of the tuberculosis survivors who were alive in 2020, we estimate that 18% (95% UI 16–20) were treated in the past 5 years and 8% (7–9) were treated in the past 2 years.

Interpretation

The number of tuberculosis survivors alive in 2020 is more than ten times the estimated annual tuberculosis incidence. Interventions to alleviate respiratory morbidity, screen for and prevent recurrent tuberculosis, and reduce stigma should be immediately prioritised for recently treated tuberculosis survivors.

Funding

UK Medical Research Council, the UK Department for International Development, the National Institute for Health Research, and the European and Developing Countries Clinical Trials Partnership.

---

### Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis [^113XtNzu]. The Lancet: Respiratory Medicine (2015). Medium credibility.

Discussion

This population-based transmission model of MDR-TB epidemics, which aims to translate notification data into estimates of MDR transmission, suggests that current estimates of MDR-TB prevalence among TB notifications are most consistent with a hypothesis that over 80% of incident MDR-TB in most present-day epidemic settings results from transmission of MDR-TB rather than selection of de novo resistance during previous treatment of the index case. To the extent that these notification data are accurate and our model is an adequate representation of TB transmission dynamics, these findings suggest that better treatment of drug-susceptible strains alone is unlikely to curb MDR-TB epidemics in most settings. Our estimates of MDR-TB transmission are robust to a wide array of sensitivity analyses and assumptions about the transmissibility of MDR strains, MDR-TB treatment practices, and TB natural history at the population level. These results should prompt further research to validate the findings of this model-based analysis and to improve these estimates by developing more accurate surveillance measures of drug resistance and by clarifying TB natural history and transmission-related parameters. A predominance of MDR transmission as the etiology of new MDR cases should motivate the global TB community to expand resource outlays and infrastructure for the rapid diagnosis and effective treatment of MDR-TB.

---

### Estimating the impact of tuberculosis pathways on transmission-what is the gap left by passive case finding? [^111sLy61]. The Journal of Infectious Diseases (2024). Medium credibility.

We defined 3 categories of mutually exclusive pathways to explore contributions to transmission by individuals who developed infectious disease within 10 years of Mtb infection. First, we examined trajectories over the 10-year course of disease: (1) progression included individuals who never reenter a previous disease state after reaching a more advanced state; (2) regression included individuals who reentered subclinical or noninfectious states after progressing to more advanced disease and never again progressed to a more advanced state; (3) undulation included individuals who progressed, regressed, and then progressed again between states (ie, those who experienced at least 2 changes of direction). Second, we classified individuals based on the time between infection and onset of infectious (subclinical or clinical) disease: rapid included individuals whose disease pathways included an infectious state within 24 months of infection, with the remainder classified as slow. Third, we based categories on whether individuals were eligible for PCF, defined in the main analysis as individuals who spent at least 2 consecutive months with clinical disease (in line with systematic reviews of self-reported duration of symptoms prediagnosis). Within those who were PCF-eligible, we separated a pre- and post-PCF eligibility period informed by the PCF threshold (see Supplementary Figure 2 for an illustration of pathways). From these pathways, we further distinguished how much transmission occurred during time spent in subclinical disease and how much transmission occurred during the first 24 months after infection.

The contribution of pathways and periods was calculated as a proportion of total transmission. Median values and 95% UIs are reported.

To examine the sensitivity of our results to key model assumptions, we varied the impact of relative infectiousness for subclinical disease from 0 to 1.5 times that of clinical disease and lowered the threshold for PCF eligibility to either at the start or after the first month of clinical disease.

Data and analysis code can be found at GitHub.

---

### Introducing risk inequality metrics in tuberculosis policy development [^114V2aQn]. Nature Communications (2019). High credibility.

The parameters that have been most commonly varied to explain incidence trends in modeling studies are rates of successful treatment (τ) and mean effective contacts (β). For completion and comparability with other studies we conceive additional scenarios where the observed declines in incidence are attributed to decays in τ and ω (Supplementary Fig. 2 and Supplementary Tables 5 and 7) or β and ω (Supplementary Fig. 3 and Supplementary Tables 6 and 7), and infer the respective attributions as above. In both cases the scaling in control efforts required to meet End TB incidence targets appears lower under heterogeneity. This seems counter-intuitive at first but see the values of R₀ plotted as insets in Figs. 4, 5 and Supplementary Figs. 2, 3. During the scale-up phase, this transmission index is consistently below one in the homogeneous implementation and above one when heterogeneity is considered. Since τ and β relate to ongoing transmission, scaling changes in these parameters is not effective at reducing incidence when R₀ < 1 and, consequently, the homogeneous implementations must rely on the reduction in ω alone to meet the targets. This process results in the inflation of the scale parameter κ observed under homogeneity and reversion of the default expectation. The sensitivity of our conclusions to which parameters are actually varying in each setting reinforces the need for more discriminatory data and dedicated studies.

Results presented so far addressed heterogeneity in contacts rates, which implicitly considers that acquisition of infection is positively correlated with transmission to others. But irrespective of how present heterogeneity in contact rates is in TB dynamics, there is a myriad of biological factors which contribute to making individuals different and may affect TB incidence patterns.

Figure 6 (and Supplementary Table 8) shows the results obtained by employing the same procedures as in Fig. 5 but assuming that heterogeneity affects susceptibility of infection given exposure, rather than the rate of contacts. The two variants are in fact described by the same model, except for how the force of infection is formulated (Methods). Essentially, if we write the force of infection as λ = β(ρ₁I₁ + ρ₂I₂), where the new parameters ρ₁ and ρ₂ represent the relative infectivities of individuals in risk groups 1 and 2, respectively, heterogeneity in contact ratesis retrieved when ρᵢ = αᵢ and heterogeneity in susceptibilityis obtained by imposing ρᵢ = 1, while a combination of the two would correspond to values in between.

---

### Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries [^113qndCe]. BMC Medicine (2019). Medium credibility.

Background

Tuberculosis (TB) control efforts are hampered by an imperfect understanding of TB epidemiology. The true age distribution of disease is unknown because a large proportion of individuals with active TB remain undetected. Understanding of transmission is limited by the asymptomatic nature of latent infection and the pathogen's capacity for late reactivation. A better understanding of TB epidemiology is critically needed to ensure effective use of existing and future control tools.

Methods

We use an agent-based model to simulate TB epidemiology in the five highest TB burden countries-India, Indonesia, China, the Philippines and Pakistan-providing unique insights into patterns of transmission and disease. Our model replicates demographically realistic populations, explicitly capturing social contacts between individuals based on local estimates of age-specific contact in household, school and workplace settings. Time-varying programmatic parameters are incorporated to account for the local history of TB control.

Results

We estimate that the 15-19-year-old age group is involved in more than 20% of transmission events in India, Indonesia, the Philippines and Pakistan, despite representing only 5% of the local TB incidence. According to our model, childhood TB represents around one fifth of the incident TB cases in these four countries. In China, three quarters of incident TB were estimated to occur in the ≥ 45-year-old population. The calibrated per-contact transmission risk was found to be similar in each of the five countries despite their very different TB burdens.

Conclusions

Adolescents and young adults are a major driver of TB in high-incidence settings. Relying only on the observed distribution of disease to understand the age profile of transmission is potentially misleading.

---

### Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis [^114S1eNC]. BMC Medicine (2022). Medium credibility.

Methods

We modelled the impact of future preventive treatment regimens in four countries: South Africa, Kenya, India, and Brazil. As shown in Table 1, South Africa and Kenya are high TB burden countries where HIV is a major driver of the TB epidemic; India is a high TB burden country where HIV does not play such a driving role; and Brazil is the country with the lowest incidence and mortality rates of the four. These countries also represent a range of socioeconomic settings, ranging from low-income to upper middle-income. For each country, we developed a deterministic, compartmental model of TB transmission dynamics, capturing HIV coinfection and the provision of antiretroviral therapy, as well as the implementation of preventive treatment amongst all-age household contacts of notified TB cases (see Fig. 1 for model schematic and Additional file 1: Fig. S1 and Table S1 for further technical specifications, including model equations) The model incorporates the acquisition and transmission of rifampicin-resistant (RR) TB including multi-drug-resistant TB. It also incorporates the accelerating effect of HIV coinfection on TB progression. For simplicity, the model does not incorporate age structure, nor does it distinguish different forms of TB (e.g. smear status or extrapulmonary vs pulmonary TB), instead assuming an average infectiousness over these forms. For natural history parameters relating to TB infection, we drew from recent systematic reviews and modelling studies that identified models consistent with available data for TB progression (see Additional file 2: Table S2). As described below, we accommodated a range of possible mechanisms by which a future preventive treatment regimen would alter these dynamics.

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^113f9pWt]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Future TB Incidence

Figure 2A shows future U.S. TB incidence estimates when the three scenarios are applied to all countries collectively. In the base-case scenario, the overall incidence was projected to be 2.9 (95% uncertainty interval, 2.5 to 3.2) per 100,000 in 2020 and to decline to 2.5 (95% uncertainty interval, 2.1 to 3.1) per 100,000 by 2035, a 12% (95% uncertainty interval, −5% to 24%) reduction. In the optimistic scenario (assuming all countries achieve WHO End TB Strategy incidence targets for 2035), this reduction was projected to be 49% (95% uncertainty interval, 44–55%) for an incidence rate of 1.4 (95% uncertainty interval, 1.2–1.7) per 100,000 in 2035, which is 43% (95% uncertainty interval, 34–54%) lower than the base-case scenario in the same year. In the pessimistic scenario (with incidence in all countries stagnating at current levels), the U.S. incidence rate was projected to be approximately level, dropping by just 1% (95% uncertainty interval, −13% to 12%) over 2020–2035 for an incidence rate of 2.9 (95% uncertainty interval, 2.5 to 3.2) per 100,000 in 2035, which is 12% (95% uncertainty interval, 4% to 23%) higher than the base-case scenario.

---

### Estimating the population at high risk for tuberculosis through household exposure in high-incidence countries: a model-based analysis [^117WNrbn]. EClinicalMedicine (2021). Medium credibility.

Our country-specific estimates have important implications for policy. The UN High-Level Meeting on TB set an ambitious target to reach 20 million household contacts ages five and older for TPT by 2022, though current progress is far short of this target. These estimates provide country-specific information to help reach this goal in the 20 countries that had more than 80% of the global total of new TB cases in 2019. As estimated for child household contacts globally or in the WHO Southeast Asia region, future modeling studies could build on this work by estimating the impact of reaching household contacts of all ages in averting TB disease and death and the associated cost. Household contact investigation studies continue to show the benefit of TPT among household contacts of all ages, including the recent study by Paradkar et al reporting that 2% of household contacts at study sites in India developed TB in the first 24 months of follow-up. The feasibility of scaling up household contact investigation to reach this larger population remains a concern, particularly in light of the negative impact of the COVID-19 pandemic on essential TB services globally. However, the shared importance of household contact investigation in response to TB and COVID-19 has been identified as an opportunity to address both infections in parallel.

In conclusion, we estimated that the recent recommendation that household contacts ages five and older in high-incidence countries may receive TPT could expand the eligible population by more than 7-fold. This population is even larger than the target set at the 2018 UN High-Level Meeting on TB. Successfully reaching these household contacts for clinical evaluation and TPT may avert substantial TB-related morbidity and mortality.

---

### Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis [^115sE4Ds]. BMC Medicine (2022). Medium credibility.

Table 1
Comparison of countries in analysis. Shown are estimates for total annual TB incidence rates, and TB incidence among HIV+ only in 2019, drawn from the WHO Global TB Report 2019. While these estimates are shown for comparison, we also calibrated each model to country-specific data for TB mortality, notifications, the burden of rifampicin-resistant TB, and the coverage of antiretroviral therapy (ART) amongst those with PLHIV. Full country data used for calibration are listed in Additional file 4: Table S4

Despite their simplicity and transparency, compartmental models do not lend themselves readily to modelling contacts of patients with TB disease. To address this challenge, our approach relies on recent data that suggests that the incidence rate in TB-infected household contacts of TB cases is 7–8 times greater than in the general population; this is because infections amongst contacts are more likely to have arisen from recent exposure than infections in the community. As described in Additional file 3 (Fig. S2, Table S3), our strategy is to model explicitly this disproportionate amount of recent infection in household contacts. An advantage of this approach, compared to previous modelling analyses of preventive treatment, is that it allows us to incorporate the mechanisms by which future preventive regimens may act (mechanisms discussed further below).

Calibration

For each country, we calibrated the model to country-specific estimates for TB incidence and mortality, incidence of RR-TB; the proportion of incident TB associated with concomitant HIV infection and the coverage of antiretroviral therapy (ART) amongst those living with HIV (PLHIV), as well as the coverage of current preventive treatment amongst those initiated on ART (Table 1). All of these estimates include uncertainty intervals: we used Bayesian melding to systematically propagate this uncertainty to model projections, assuming uniform priors on model parameters. Drawing 1000 posterior samples, we estimated Bayesian credible intervals (CrI) in model projections using 2.5th and 97.5th percentiles, and central estimates using the 50th percentile. Further details of model calibration can be found in Additional file 4.

---

### Drivers of tuberculosis transmission [^11739yoS]. The Journal of Infectious Diseases (2017). Low credibility.

However, determining where tuberculosis transmission specifically occurs outside of households is considerably more challenging. The potential for airborne transmission to occur even during brief exposures, combined with the variable periods of latency, make establishing specific tuberculosis transmission linkages exceptionally difficult. Despite these challenges, certain specific settings have been identified as substantial contributors to tuberculosis risk. Nosocomial transmission was a major driver of MDR-TB outbreaks in the United States, Spain, and Italy in the 1990s; hospital-associated transmission was also responsible for the explosive dissemination of XDR-TB in a rural South African district in the mid-2000s. Homeless shelters have been frequently identified as drivers of tuberculosis outbreaks. Prisons have similarly been sources of not only incident outbreaks in low-burden countries but also high levels of endemic transmission in low-income and middle-income countries. Using national tuberculosis notification data from Brazil, Bourdillon et al found that > 25% of all incident cases among men aged 20–29 years occurred within prisons, where notification rates were 31 times greater than in the general population. Other high-risk community settings implicated in tuberculosis transmission include public transportation, churches, schools, bars, and slums.

The concentration of tuberculosis transmission in certain settings and subpopulations also leads to transmission heterogeneity, which can act to increase the effective reproductive number and may make control of transmission more difficult. Basu et al described these settings as "institutional amplifiers" and demonstrated how they can increase incidence even when high levels of case detection and treatment success are established in the broader community. By understanding the settings and groups at high risk for tuberculosis, however, we can more efficiently target interventions to achieve tuberculosis control. For example, Dowdy et al modeled data from Rio de Janeiro and demonstrated that targeting interventions to high-risk slum areas where 6% of the population resides could be as effective in reducing tuberculosis as equivalent measures conducted for the other 94% of the population.

---

### Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation disease [^1174ZbEJ]. BMC Medicine (2015). Low credibility.

Methods

The present study utilizes the Disease Transmission Kernel (DTK) model developed by the Institute for Disease Modeling group at Intellectual Ventures. The model and all necessary input files are available by request at the Institute for Disease Modeling website. Additional file 1 details the model structure, assumptions, and a complete list of model inputs. The model schematic is included in Figure 1. The fit of the mean trajectory to the data during the calibration time period is shown in Figure 2.

Figure 1
Model and treatment schematic. A. Model schematic. Individuals are born healthy and may subsequently acquire latent TB infections through transmission. Disease progresses through latent disease, binned into latent fast or latent slow, through an active presymptomatic phase, and to active symptomatic disease. Individuals in the active presymptomatic and active symptomatic phases are infectious (excluding those with extrapulmonary TB). At the start of active disease, individuals may seek treatment. Individuals may die from non-disease mortality at any phase, but disease mortality only occurs in the active symptomatic phase. B. Treatment pathways. Individuals seek treatment either in the CDC or in private hospitals. Once on treatment, they can either be cured, relapse, fail, or die during treatment. Individuals who fail treatment in hospitals can seek retreatment in the CDC or again seek treatment in hospitals. See Additional file 1 for additional details on how the disease progression and treatment pathways were handled in the model.

Figure 2
Model calibration to available data. A. TB Prevalence, data from. B. Smear positive TB prevalence, data from. C. Mortality, data from. D. MDR, data from. E - F. Age-dependent smear positive prevalence in 1990 and 2000. G. Incidence, WHO estimate not used for calibration but shown for comparison. H. Breakdown of sources of incidence, model estimate. Solid black line is mean of model output, gray shaded area is 95% credible interval including both parameter and stochastic uncertainties. Red squares represent data (as cited) with reported 95% credible interval.

Model population

We use a simulated population of 500,000 individuals in 1990 that grows to 720,000 by 2035. This represents a 0.05% sampling of the true population size in China. The absolute population value was chosen to reflect available computational resources. The change in population is driven by the UN Population database estimates for medium fertility and age-disaggregated non-TB mortality. The overall population growth is shown in Additional file 1: Figure S1.

---

### World TB day-March 24, 2019 [^117KzR2Q]. MMWR: Morbidity and Mortality Weekly Report (2019). Medium credibility.

World TB Day is observed each year on March 24. This observance provides an opportunity to raise awareness about tuberculosis (TB) and the measures needed to find, treat, and prevent this devastating disease.

---

### Epidemiology of tuberculosis and progress toward meeting global targets-worldwide, 2019 [^117QTDP9]. MMWR: Morbidity and Mortality Weekly Report (2021). Medium credibility.

Source: Adapted from World Health Organization. Global tuberculosis report 2020. Geneva, Switzerland: World Health Organization; 2020.

Abbreviation: CFR = case-fatality rate.

* Number of cases per 100,000 population.

† Includes multidrug-resistant TB.

During 2019, multidrug-resistant (MDR) TB illness (TB that is resistant to at least isoniazid and rifampicin, the two most potent anti-TB drugs) or rifampicin-resistant TB illness (RR-TB) developed in an estimated 465,000 persons. These patients accounted for 4.7% of all persons with TB, 3.3% of persons with a new TB diagnosis, and 18% of persons previously treated for TB.

Most persons who became ill with TB in 2019 lived in the WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%), with smaller percentages in the Eastern Mediterranean (8.2%), the Americas (2.9%), and Europe (2.5%) (Table). Eight countries accounted for two thirds of the total global TB cases: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%), and South Africa (3.6%). The WHO European and African regions have experienced the largest declines in incidence (19% and 16%, respectively) and mortality (31% and 19%, respectively) since 2015.

If persons who received a TB diagnosis that was reported to national authorities are assumed to be treated for TB, then in 2019, a total of 7.1 million persons were treated for TB, a slight increase from 7.0 million in 2018. With an estimated 10 million incident cases, this leaves a gap of 2.9 million persons with incident TB who either did not receive a diagnosis or did receive a diagnosis but were not reported to national authorities. Among the estimated 815,000 HIV-infected persons with cases of incident TB, 456,426 (56%) persons were reported as having received a diagnosis and been treated. Among the estimated 465,000 persons with incident MDR or RR-TB, only 177,099 (38%) were enrolled in MDR or RR-TB treatment.

---

### Global epidemiology of tuberculosis and progress toward meeting global targets-worldwide, 2018 [^113LA2Vk]. MMWR: Morbidity and Mortality Weekly Report (2020). Medium credibility.

In 2018, an estimated 10 million persons had incident TB (132 per 100,000 population), a 2% decline from 2017 (Figure 1). Incidence has declined by an average of 1.6% per year since 2000. In 2018, 7.0 million persons globally were notified of their TB-positive results, representing 70% of the estimated number of persons with incident TB, an increase from the 6.4 million persons (64%) notified in 2017. In 2018, 69% of all persons with incident TB received anti-TB treatment, compared with 64% in 2017. The estimated number of TB-related deaths declined 5%, from 1.57 million in 2017 to 1.49 million in 2018 (CFR = 15%) (Figure 2). An estimated 862,000 persons living with HIV had incident TB in 2018, accounting for 8.6% of all persons with TB. Within this group, the estimated annual TB incidences were 6% in 2000, 2.5% in 2017, and 2.3% in 2018. In 2018, an estimated 251,000 TB deaths among persons living with HIV occurred (CFR = 29%). Overall, an estimated 484,000 persons had incident rifampicin-resistant or multidrug–resistant TB in 2018, representing 4.8% of all persons with TB, 3.4% of persons with a new TB diagnosis, and 18% of persons previously treated for TB. An estimated 214,000 persons died of either rifampicin-resistant or multidrug–resistant TB (CFR = 44%) in 2018. Among persons with rifampicin-resistant TB, 78% were estimated to have multidrug–resistant TB.

---

### Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries [^111dQ6s2]. BMC Medicine (2019). Medium credibility.

Social mixing

Individuals interact through social contacts that occur in four different contexts: households, schools, workplaces and other locations. A social contact is considered conceptually as either a physical contact or a two-way conversation involving three or more words (consistent with reporting of input data). All individuals of the same household are assumed to contact each other every day. In contrast, social contacts occurring within congregate settings (schools and workplaces) and in other locations are generated stochastically at each time step. Their frequency and age assortativity pattern are derived for each country from estimates of the location- and age-specific contact matrices. A detailed description of our approach to contact generation in the different settings is provided in Section 2.3 of Additional file 1.

TB model

Figure 1 illustrates the infection stages simulated. Age-specific parameters derived from empiric data are used to determine whether and when infected individuals progress to active disease. Active cases may be smear-positive, smear-negative or extrapulmonary TB and will either spontaneously cure or die from their disease in the absence of treatment. The type of natural history outcome and the time at which it occurs are randomly generated based on the TB natural history characteristics observed during the pre-chemotherapy era (see Additional file 1, Section 3.1).

M.tb transmission may occur when a person with active TB contacts a susceptible individual. The baseline probability that a social contact leads to transmission is calibrated to observed national TB prevalence aggregated for all ages (Additional file 1, Section 4). Empirical estimates of the age-specific TB prevalence (for all countries except India due to absence of data) were compared to model outputs for independent validation but were not used for calibration. We assume that school contacts are less likely to lead to transmission than household contacts (relative risk: RR = 0.89), as are work contacts (RR = 0.82) and other contacts (RR = 0.75). These relative risks are based on the reported proportions of high-intensity contacts by location, combined with the assumption that low-intensity contacts are half as likely to lead to transmission as high-intensity contacts (Additional file 1, Section 3.2), with sensitivity analyses used to explore alternative assumptions. The transmission probability also depends on the characteristics of the two individuals making contact, as described in Table 1.

---

### Use of modeling to inform tuberculosis elimination strategies [^113vWtW4]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Because the models used by Menzies and colleagues are based on parameters of TB epidemiology in California, the implementation and impact of the intervention scenarios will be different in other parts of the United States. Strategies to reduce TB transmission, stem the importation of M. tuberculosis, and expand LTBI testing and treatment in high-risk communities must be adapted to reflect local resources and sociopolitical contexts. Understanding the dynamics of TB epidemiology is critical for tailoring decisions and prioritizing interventions at a local program level.

All of the scenarios in these models assume the presence of a political commitment to sustain funding for the current policies and practices of domestic TB control programs. Although the recent decline in TB incidence is remarkable, it is challenging for many local health departments to maintain their current priority activities, such as case management and contact investigations. We must support these core TB control activities, which are essential to cure patients with TB and protect the public. Furthermore, it is crucial to invest in research and superior diagnostics that can accurately predict who will progress to active TB disease, to identify shorter and better-tolerated LTBI regimens, and to use implementation science to improve the effectiveness of care. It will take a substantial commitment to accelerate the pace of TB elimination, and this commitment must be sustained if we are to reach our audacious goal in this century.

---

### The health impact of identifying a person with tuberculosis through systematic screening [^117D57QP]. The Lancet: Infectious Diseases (2025). High credibility.

In estimating the cost-effectiveness of population-based screening for TB, a major gap in our knowledge is a unified estimate of health utility – for example, the number of disability-adjusted life years (DALYs) averted or quality-adjusted life years (QALYs) gained – per person with TB detected through screening and subsequently treated. Whereas the costs and yield (i.e. number of people detected) for any given screening program can be directly measured by the program itself, the corresponding health impact – which includes reductions in transmission and post-TB morbidity – can only be indirectly estimated. As a result, most economic evaluations of mass screening have not attempted to assign a health utility value to early case detection, and have instead estimated only the cost per case detected or treated. – When the long-term health impact associated with active case-finding has been estimated, those estimates have been prone to substantial bias. For example, it is often assumed that infectiousness, symptom burden, detectability, and mortality risk are consistent over time and among all people with TB, – thereby implicitly suggesting that the people found to have TB during screening are representative of people with TB in the population as a whole. Furthermore, analyses of the impact of early case detection often consider counterfactual outcomes under passive case detection in only limited fashion. – Attempts to estimate post-TB sequelae averted by early detection have been extrapolated from published estimates that were not designed for that purpose. Finally, the amount of Mtb transmission that is averted through early detection is difficult to quantify.

For all these reasons, there is currently no consensus estimate of the number of incremental DALYs averted (or QALYs gained) per person with TB detected early through population-based screening. Partially as a result of this evidence gap, a WHO-convened evidence review in 2020 found no studies that could adequately inform assessment of the cost-effectiveness of systematic screening for TB. We therefore sought to develop such an estimate through a novel conceptual approach, supported by quantitative modeling and evidence from the scientific literature.

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^115dCgUx]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Figure 2.
Projections of future tuberculosis (TB) incidence for the total population, U.S.-born population, and non–U.S.-born population in different scenarios for TB trends applied to all birth countries. (A) Total population. (B) U.S.-born population. (C) Non-U.S.-born population. Vertical axes are scaled to represent percentage changes equally in each panel. Solid lines represent best estimates for each scenario. Shaded regions represent 95% uncertainty intervals.

Figures 2B and 2C show TB incidence projections by scenario for U.S.-born and non–U.S.-born populations. U.S.-born incidence rates were projected to be 0.91 (95% uncertainty interval, 0.79–1.03) per 100,000 in 2020 and to decline by 43% (95% uncertainty interval, 36–48%) in the base-case scenario, reaching 0.51 (95% uncertainty interval, 0.43–0.61) per 100,000 in 2035. U.S.-born trends showed minor differences between optimistic and pessimistic scenarios, producing a 55% (95% uncertainty interval, 53–58%) reduction and a 40% (95% uncertainty interval, 33–44) reduction in incidence rates over 2020–2035, respectively. These modest differences are not surprising because the U.S.-born population is only indirectly impacted through changes in secondary transmission from non–U.S.-born individuals. Incidence rates for the non–U.S.-born population were projected to be 15 (95% uncertainty interval, 13 to 17) per 100,000 in 2020 and to remain stagnant, with an estimated decline of 7% (95% uncertainty interval, −10% to 22%) to reach 14 (95% uncertainty interval, 11 to 17) per 100,000 in 2035. The two alternative scenarios were projected to diverge rapidly, with a 51% (95% uncertainty interval, 46% to 58%) reduction 2020–2035 with the optimistic scenario and a potential 5% (95% uncertainty interval, −5% to 19%) increase with the pessimistic scenario.

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^111z9B4W]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Results

Figure 1A shows reported U.S. TB cases and modeled TB estimates from 2000 to 2035 with the base-case scenario. Over 2020–2035, modeled U.S.-born TB cases declined at an average of 3.2% (95% uncertainty interval, 2.5 to 3.8) per year, whereas non–U.S.-born and total TB cases were relatively flat (averaging a 0.6% [95% uncertainty interval, −0.6% to 1.9%] increase and a 0.3% [95% uncertainty interval, −0.9% to 1.3%] decline per year, respectively). During this period, the fraction of TB cases among non–U.S.-born individuals increased to 83% (95% uncertainty interval, 80–85%), with 25% (95% uncertainty interval, 20–31%) among non–U.S.-born individuals within 2 years of U.S. arrival (Figure 1B) (compared with 70% and 17%, respectively, in 2017).

Figure 1.
Estimated tuberculosis (TB) cases in the United States compared with reported data and projected cases to 2035 in the base-case scenario. (A) Total annual TB cases for U.S.-born, non–U.S.-born, and total populations (2000–2035). (B) Contribution of non–U.S.-born individuals and recent migrants to total annual U.S. TB cases (2000–2035). Lines represent multiple simulated epidemic trajectories. Recent entry indicates TB diagnosis with 2 years of U.S. entry.

---

### Guidelines for multi-model comparisons of the impact of infectious disease interventions [^115N51kG]. BMC Medicine (2019). Medium credibility.

Exploring variability

Between- and within-model variability and uncertainty should be explored

Exploring between- and within-model variability and uncertainty is a fundamental part of the model comparison. Scenario and sensitivity analyses should be part of the iterative process; the results of these analyses may lead to changes in the models and to refining of the research question (Fig. 2). It may be important to explore different implementation strategies or to evaluate the impact of the intervention in a variety of settings (e.g. with different transmission characteristics) to inform decision-makers.

Fig. 2
The multi-model harmonisation and comparison process

Good practice

Multiple scenarios should be explored to understand the drivers of the model results

To show the variability between models, a range of different decision scenarios and outcomes should be explored. As is performed for individual models, a base-case scenario can be explored, followed by several different scenarios. These scenarios should include those most relevant to decision-makers but might also reflect different hypotheses, for example, based on epidemiological theory and previous modelling studies, on which model attributes might explain differences in model predictions or outcomes. Scenarios outside of the immediate relevance to the policy decision might allow for a revealing comparison of the impact of important parameters that vary among models. By separately modifying the different aspects of the model (e.g. biological, behavioural and demographic model parameters), it is possible to assess the sensitivity of model output to alternative model structures. This allows modellers to explore and explain the cause of different results.

If the model comparison includes many models, it is possible to explore between-model variation and heterogeneity in projected impact using a statistical approach such as a (univariate) meta-regression analysis.

Sensitivity analysis and what-if analyses (examining extreme scenarios) should be carried out

Presenting the variability between models is one of the core objectives of the model comparison exercise. However, not only between-model heterogeneity should be explored; within-model uncertainty should also be assessed through sensitivity analysis. One possibility is examining extreme scenarios such as a best-case and a worst-case scenario, where all parameters are set at extreme but plausible values that are favourable or unfavourable. Ideally, probabilistic sensitivity analysis should also be performed. Probabilistic sensitivity analysis reflects the combined effects of uncertainty in the value of all the parameters and provides confidence intervals around point estimates (e.g. the base-case results) for each of the models. Performing sensitivity analysis for multiple models allows for the testing of the boundaries of consensus.

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^1115naQy]. Nature Communications (2023). High credibility.

Dynamics of population immunocompetence

We developed a simplified version of the deterministic compartmental AIM model of age- and sex-specific HIV incidence that is used in official UNAIDS estimates. This model includes both sexes (s), 81 single-year age groups (g), 8 HIV and CD4 cell count categories (HIV-negative, and ≥ 500, 350–499, 250–349, 200–249, 100–199, 50–99, and < 50 cells per mm 3, which we denote h), and 4 ART categories among PLHIV (no ART, 0–6 months, 7–12 months, 12+ months, which we denote r = 0,.3) for a total of 5184 compartments. We assumed that a TB incidence rate ratio (IRR) at time t in each country applied to HIV-related states given by a two-parameter model (ρ controlling the interaction between CD4 decrement and TB risk; α controlling the protection from TB due to ART), irr(t, s, g, h, r | α,ρ) = < α r/3 exp[ρΔ h] >, where <… > denotes an average over CD4 cell decrement below 1000 cells/mm 3 (Δ h) in state h; α captures the protection from ART in states r = 0,.3. We used a heuristic pursuit algorithm to achieve fit of this model to the HIV prevalence and ART coverage data used as inputs in the UNAIDS estimates. To facilitate inference, we used the AIM model to calculate mean IRRs and mortality for a model with simpler age (5-year age categories, a) and HIV/ART structure (X = U for HIV-negative, H for HIV-infected/ART-naive, A for on ART), for example defining IRR X (t, s, a | α,ρ) = < irr(t, s, g, h, r | α,ρ) >, where <… > denotes an average over the fine-grained age and HIV/ART states { g, h, r } corresponding to the state { a, X }. Because parameters α and ρ are uncertain and need to vary for inference, we emulated the dependence of these AIM-derived IRRs on α and ρ by running the model for a grid of α and ρ values and constructing a fast and accurate log-bilinear interpolation approximation to IRR X (t, s, a | α,ρ) for each country (see Supplementary Information).

---

### Global estimates of paediatric tuberculosis incidence in 2013–19: a mathematical modelling analysis [^111W8zfq]. The Lancet: Global Health (2022). High credibility.

Model parameters

We used Bayesian methods to implement the analysis. We specified probability distributions representing available evidence for each parameter. For the duration of untreated tuberculosis disease (d untx), we assumed a mean of 3.00 years (range 2.50–3.50), on the basis of historical cohort data. For the proportion of time spent in subclinical disease (f), we assumed a mean fraction of 0.25 (0.17–0.33), equivalent to 9 months (6–12), on the basis of research describing a large proportion of individuals who were asymptomatic among prevalent tuberculosis cases. For the probability of infection per infectious contact (b), we divided an estimate of the effective contact rate (12 [6–15], the annual number of infections caused by an infectious case in a susceptible population), by the average annual number of contacts for children. For the probability of progression to tuberculosis disease for newly-infected individuals (a j), we used a value of 0.19 (range 0.08–0.37) for children aged 0–4 years, and 0.09 (0.05–0.16) for children aged 5–14 years. For the rate of contact saturation (q), whereby overall transmission is reduced by infectious contacts being concentrated within a small number of individuals, we specified a weak previous distribution centred at 0.50 (range 0.10–0.90) and estimated this value through calibration. For the risk ratio of disease with untreated HIV (m h), we specified a value of 7.90 (range 4.50–13.70). For the risk ratio of disease with treated HIV compared with untreated HIV (m t), we specified a value of 0.30 (0.21–0.39). For the risk ratio of disease with underweight (m u), we specified a value of 4.0 (2.0–6.0), on the basis of a review of observational cohort studies. For the risk ratio of disease with BCG vaccination (m V k), we specified country-specific values based on evidence showing greater BCG vaccine effectiveness at higher latitudes. For each parameter, we specified probability distributions to produce mean values and 95% uncertainty interval widths matching the values given previously (appendix 1 p 6). Other inputs and analytical code are provided in a Dataverse online repository.

---

### New and improved tuberculosis diagnostics: evidence, policy, practice, and impact [^113fG1dc]. Current Opinion in Pulmonary Medicine (2010). Low credibility.

Purpose Of Review

The aim is to summarize the evidence base for tuberculosis (TB) diagnostics, review recent policies on TB diagnostics, and discuss issues such as how evidence is translated into policy, limitations of the existing evidence base, and challenges involved in translating policies into impact.

Recent Findings

Case detection continues to be a major obstacle to global TB control. Fortunately, due to an unprecedented level of interest, funding, and activity, the new diagnostics pipeline for TB has rapidly expanded. There have been several new policies and guidelines on TB diagnostics. However, there are major gaps in the existing pipeline (e.g. lack of a point-of-care test) and the evidence base is predominantly made up of research studies of test accuracy.

Summary

With the availability of new diagnostics and supporting policies, the next major step is translation of policy into practice. The impact of new tests will depend largely on the extent of their introduction and acceptance into the global public sector. This will itself depend in part on policy decisions by international technical agencies and national TB programs. With the engagement of all key stakeholders, we will need to translate evidence-based policies into epidemiological and public health impact.

---

### Beyond latent and active tuberculosis: a scoping review of conceptual frameworks [^111oyavN]. EClinicalMedicine (2023). Medium credibility.

Infectiousness and disease threshold

To assess the epidemiological significance of each disease state, articles were reviewed for the terms "infectious" or "transmissible". To understand at which state articles considered TB disease to begin (disease threshold), the term "disease" was reviewed. These terms were included in the terminology, narrative descriptions or as part of conceptual diagrams for disease states. No article attributed the term infectious or disease to describe States 0, I or II. States IV and V were most frequently described as infectious (n = 12/40; 30% and n = 16/40; 40% respectively) and as disease (n = 12/40; 30% and n = 22/40; 55% respectively).

---

### Using passive surveillance to maintain elimination as a public health problem for neglected tropical diseases: a model-based exploration [^112uxMtq]. Clinical Infectious Diseases (2024). Medium credibility.

Reproduction Number

The basic reproduction number, R₀, is the average number of infections generated by a single (average) infected individual in a wholly susceptible population. This can also be evaluated when interventions are in place, sometimes called the reproduction number under control (Rᴄ) or, more commonly, the effective reproduction number (R). For this scenario we consider that there is no immunity in the population during the postvalidation period.

The R₀ for infection dynamics only (no detection or treatment) is given by the probability that an individual survives to the infectious period, the transmission rate, and the average duration of infectiousness (see Supplementary Material - Appendix 2):

When passive detection and treatment are present, a proportion of individuals are detected and then treated. The expression of the effective reproduction number for this model is

The first part of the expression represents an individual who is not passively detected, multiplied by the probability that they move from exposed to infectious before dying. The number of secondary infections they will contribute depends on the transmission rate while infectious, multiplied by the duration of infectiousness while in the infectious class.

The second part of the expression represents an individual who is passively detected, multiplied by the probability that they move from exposed to infectious before dying. The number of secondary infections they will contribute depends on the transmission rate while infectious, multiplied by the duration of infectiousness while in the detected class, which is usually determined by the delay between diagnosis and treatment.

Improve Detection or Improve Time to Treatment?

To investigate the benefits of detecting more infections versus treating people quicker once they are detected, we consider the effect of changing these parameter values on the R. We define the 2 parts of the R expression as undetected transmissionsand detected transmissions.

The value of the detected and undetected parts of the R expression were calculated for different proportions of new infections detected, that is, the proportion of infections that are detected when infectious and for different reductions in the duration of infectiousness once detected (achieved by increasing treatment rate; see Supplementary Material - Appendix 2).

We consider 2 example diseases; one disease with an underlying (no detection or treatment)close to the threshold of 1, and a second with a higher representing a disease dynamic similar to leprosy (range, 1.74–2.36; unpublished data). In both cases we assume the same transmission rate but a different recovery rate of 1/3.5 years and 1/7 years, respectively, (leprosy type parameters adapted from).

---

### Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study [^115XDGHU]. The Lancet: Global Health (2018). Medium credibility.

Background

In high-incidence settings, recurrent disease among previously treated individuals contributes substantially to the burden of incident and prevalent tuberculosis. The extent to which interventions targeted to this high-risk group can improve tuberculosis control has not been established. We aimed to project the population-level effect of control interventions targeted to individuals with a history of previous tuberculosis treatment in a high-incidence setting.

Methods

We developed a transmission-dynamic model of tuberculosis and HIV in a high-incidence setting with a population of roughly 40000 people in suburban Cape Town, South Africa. The model was calibrated to data describing local demography, TB and HIV prevalence, TB case notifications and treatment outcomes using a Bayesian calibration approach. We projected the effect of annual targeted active case finding in all individuals who had previously completed tuberculosis treatment and targeted active case finding combined with lifelong secondary isoniazid preventive therapy. We estimated the effect of these targeted interventions on local tuberculosis incidence, prevalence, and mortality over a 10 year period (2016–25).

Findings

We projected that, under current control efforts in this setting, the tuberculosis epidemic will remain in slow decline for at least the next decade. Additional interventions targeted to previously treated people could greatly accelerate these declines. We projected that annual targeted active case finding combined with secondary isoniazid preventive therapy in those who previously completed tuberculosis treatment would avert 40% (95% uncertainty interval [UI] 21–56) of incident tuberculosis cases and 41% (16–55) of tuberculosis deaths occurring between 2016 and 2025.

Interpretation

In this high-incidence setting, the use of targeted active case finding in combination with secondary isoniazid preventive therapy in previously treated individuals could accelerate decreases in tuberculosis morbidity and mortality. Studies to measure cost and resource implications are needed to establish the feasibility of this type of targeted approach for improving tuberculosis control in settings with high tuberculosis and HIV prevalence.

Funding

National Institutes of Health, German Research Foundation.

---

### The global burden of tuberculosis: results from the global burden of disease study 2015 [^11722WDD]. The Lancet: Infectious Diseases (2018). Medium credibility.

Background

An understanding of the trends in tuberculosis incidence, prevalence, and mortality is crucial to tracking of the success of tuberculosis control programmes and identification of remaining challenges. We assessed trends in the fatal and non-fatal burden of tuberculosis over the past 25 years for 195 countries and territories.

Methods

We analysed 10691 site-years of vital registration data, 768 site-years of verbal autopsy data, and 361 site-years of mortality surveillance data using the Cause of Death Ensemble model to estimate tuberculosis mortality rates. We analysed all available age-specific and sex-specific data sources, including annual case notifications, prevalence surveys, and estimated cause-specific mortality, to generate internally consistent estimates of incidence, prevalence, and mortality using DisMod-MR 2.1, a Bayesian meta-regression tool. We assessed how observed tuberculosis incidence, prevalence, and mortality differed from expected trends as predicted by the Socio-demographic Index (SDI), a composite indicator based on income per capita, average years of schooling, and total fertility rate. We also estimated tuberculosis mortality and disability-adjusted life-years attributable to the independent effects of risk factors including smoking, alcohol use, and diabetes.

Findings

Globally, in 2015, the number of tuberculosis incident cases (including new and relapse cases) was 10.2 million (95% uncertainty interval 9.2 million to 11.5 million), the number of prevalent cases was 10.1 million (9.2 million to 11.1 million), and the number of deaths was 1.3 million (1.1 million to 1.6 million). Among individuals who were HIV negative, the number of incident cases was 8.8 million (8.0 million to 9.9 million), the number of prevalent cases was 8.9 million (8.1 million to 9.7 million), and the number of deaths was 1.1 million (0.9 million to 1.4 million). Annualised rates of change from 2005 to 2015 showed a faster decline in mortality (-4.1% [-5.0 to -3.4]) than in incidence (-1.6% [-1.9 to -1.2]) and prevalence (-0.7% [-1.0 to -0.5]) among HIV-negative individuals. The SDI was inversely associated with HIV-negative mortality rates but did not show a clear gradient for incidence and prevalence. Most of Asia, eastern Europe, and sub-Saharan Africa had higher rates of HIV-negative tuberculosis burden than expected given their SDI. Alcohol use accounted for 11.4% (9.3–13.0) of global tuberculosis deaths among HIV-negative individuals in 2015, diabetes accounted for 10.6% (6.8–14.8), and smoking accounted for 7.8% (3.8–12.0).

Interpretation

Despite a concerted global effort to reduce the burden of tuberculosis, it still causes a large disease burden globally. Strengthening of health systems for early detection of tuberculosis and improvement of the quality of tuberculosis care, including prompt and accurate diagnosis, early initiation of treatment, and regular follow-up, are priorities. Countries with higher than expected tuberculosis rates for their level of sociodemographic development should investigate the reasons for lagging behind and take remedial action. Efforts to prevent smoking, alcohol use, and diabetes could also substantially reduce the burden of tuberculosis.

Funding

Bill & Melinda Gates Foundation.

---

### The health impact of identifying a person with tuberculosis through systematic screening [^111AX8To]. The Lancet: Infectious Diseases (2025). High credibility.

Screening populations at high risk for tuberculosis might improve clinical outcomes and reduce transmission, but the value and cost-effectiveness of population-based screening depend on the uncertain health impact of early tuberculosis detection. In this Personal View, we propose a framework for estimating the incremental health impact of systematic screening, including effects on tuberculosis morbidity, mortality, sequelae, and transmission. Our framework accounts for the timing of screening, relative to when routine diagnosis might occur and when health effects become inevitable. We also account for the heterogeneous duration of tuberculosis, as people with longer disease courses (associated with lower mortality but more transmission) are more likely to be detected by screening. Finally, we use this framework to estimate that population-based chest x-ray screening interventions might avert 2.4 disability-adjusted life-years per person (95% uncertainty interval 0.8–7.4) found to have tuberculosis through screening-well within the cost-effectiveness thresholds for many programmes with published costs.

---

### Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis [^112wyozF]. The Lancet: Respiratory Medicine (2015). Medium credibility.

Both before and after notification-data-based constraints were applied, the estimated contribution of transmission to MDR incidence was highly sensitive to the transmissibility of MDR strains (figure 3). Before applying notification-data constraints (figure 3A), parameter values that caused a shift in overall tuberculosis epidemiology to more recent transmission rather than reactivation (eg, a higher proportion of infections progressing rapidly to active disease, or a slower reactivation rate) also increased the relative amount of transmitted versus treatment-acquired MDR TB. Once only simulations consistent with a given country's notification data were considered (figure 3B), the proportion of MDR TB that resulted from MDR TB was also sensitive to the probability of acquiring resistance during treatment and to assumptions about the responsiveness of MDR infections to first-line therapy.

Given the sensitivity of estimates to MDR strain fitness and to per-treatment probabilities of acquiring resistance, we re-evaluated our results after restricting our initial broad sampling ranges for these parameters in order to verify that our original estimates were not driven by inclusion of extreme parameter values. Data are sufficiently limited and variable that we considered the original ranges to better represent the uncertainty in our estimates, but a probability of acquired resistance 0.1%–2% per new-patient treatmentand an MDR-TB transmissibility of 0.5–0.8 relative to DS-TBare supported by data. With these restrictions, the estimated percentages of incident MDR-TB reflecting MDR transmission in the global-average scenario were 94.4% (95% UR: 76.4–98.8%) when restricted by per-treatment resistance acquisition, 96.2% (95% UR: 81.6–99.5%) when restricted by MDR strain fitness, and 94.9% (95% UR: 83.5–98.7%) when restricted by both, versus 95.8% (95% UR: 68.0%–99.6%) without the restrictions as above. Additional sensitivity analyses – (a) varying the time period over which MDR is assumed to emerge, (b) adding appropriate second-line treatment for up to half of MDR-TB patients, (c) reducing the TB reactivation or transmission rate in order to generate a declining epidemic, and (d) including a high-MDR-TB-incidence "hotspot" on a background of lower incidence – each caused no more than 2% variation in the point estimate for the fraction of incident MDR-TB cases resulting from MDR transmission (see Figure S4).

---

### Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics [^112hyUbZ]. Nature Communications (2023). High credibility.

Bayesian inference

After integrating out σ, we were left with 20 parameters whose log prior densities were added to the likelihood. Each country was fitted separately using an ensemble slice sampling MCMC implementation, using 50 chains and 2000 iterations. As sensitivity analyses, we recalibrated the model assuming: 10% of incident TB extrapulmonary; 30% of incident TB extrapulmonary; children aged 10–14 years 50% as infectious as adults.

Proportion of TB incidence from recent transmission

The proportion of incidence due to recent transmission cannot be reliably calculated as the fraction of incidence from 'fast' progressing model compartments, especially when TB/HIV IRRs mean non-negligible fractions of 'slow' progressors will develop disease within 2 years. We carefully captured the proportion of incidence due to recent transmission within 2 years in 2019 by calculating incidence in an auxiliary copy of the differential equations with zero initial conditions, populated only by the (re)infection flows in the main model during 2017–2019 (see Supplementary Information).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

---

### Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis [^111wnzMt]. The Lancet: Respiratory Medicine (2015). Medium credibility.

Methods

Model structure

We constructed a deterministic compartmental model of a historical (through 2012) adult pulmonary TB epidemic involving a drug-susceptible strain (i.e. a weighted average of all non-MDR strains) and an MDR strain in a homogeneous adult population (Figure 1). Similar to previously-published models, susceptible individuals could be infected with either strain, resulting either in immediate progression to active disease (which, after a subclinical phase, progressed to care-seeking and TB treatment) or in latent infection (a non-infectious state with a continuous ongoing probability of reactivation and progression to active, infectious disease). In this historical model of high-burden countries, we assumed that, at the population level, treatment for MDR-TB was negligible, consistent with global estimates that < 20% of incident MDR-TB was treated prior to 2013and < 10% through at least 2009. Thus, individuals diagnosed with TB were treated with first-line therapy in the primary analysis, although sensitivity analysis was performed for alternative scenarios in which 25% or 50% of all people who failed initial therapy were treated with appropriate second-line therapy, with little difference in outcomes (see supplementary material, section 1c). Probabilities of treatment outcomes – including cure, treatment failure (with or without acquired resistance), and apparent cure with subsequent relapse (also with or without acquired resistance) – depended on a patient's resistance status (MDR or DS) and treatment history (treatment-naïve DS or previously-treated DS). Previously-treated individuals were assumed to have worse outcomes because of accumulated resistance to isoniazid or other single drugs, more advanced disease, or patient characteristics that contributed to their initial failure.

---

### How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in south Africa, China, and India [^112QrpWK]. BMC Medicine (2014). Low credibility.

Economic evaluation

We calculate TB-specific DALYs as the sum of years of life lost plus years of life with disability over a time horizon of one to ten years. To estimate years of life with disability, we use disability weights for TB and HIV from the Global Burden of Disease Study 2010. To relate the cost per case detected by ACF to its cost-effectiveness, we calculate the number of cases detected and treated under the counterfactual (no intervention) scenario and compare this to the number of cases detected and treated with ACF in place. We then calculate the incremental cost of the intervention as:and the incremental cost-effectiveness ratio (ICER, expressed in year 2012 US dollars per DALY averted) as:

Thus, after estimating the number of incremental cases detected and the incremental DALYs averted from the transmission model, and taking estimates of the cost per case treated, we can calculate the ICER as a function of the cost per case detected (Additional file 1).

We adopt the perspective of the national TB program (assumed to be responsible for ACF campaigns and treatment of TB, but not HIV) and discount all future costs and health outcomes at 3% per year. Since the cost-effectiveness of ACF depends strongly on the analytic time horizon (becoming less cost-effective if future cases averted are ignored), we vary the time horizon from 1 to 10 years. Thus, for 2-year campaigns, we consider effects for up to 8 years after the campaign ends. We define interventions with an incremental cost per DALY averted less than 2012 per capita gross domestic product (GDP) as highly cost-effective.

Sensitivity and uncertainty analysis

We conducted one-way sensitivity analyses for key model parameters with a focus on the cost-effectiveness threshold (i.e. maximum cost per-case detected for an ICER equal to each country's per capita GDP) for 2-year campaigns at 2-, 5-, and 10-year analytic horizons. We also conducted multivariate uncertainty analyses by selecting 20,000 parameter sets from independent prior beta distributions using Latin Hypercube sampling (Additional file 1). We calculated the cost-effectiveness thresholds from each run and used the 2.5 th and 97.5 th percentiles as the 95% uncertainty ranges. To compare the effect of each parameter, adjusted for all other parameters, we calculated partial rank correlation coefficients from the multivariate uncertainty analyses.

---

### Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis [^112vpBdW]. Nature Communications (2023). High credibility.

In 2020, almost half a million individuals developed rifampicin-resistant tuberculosis (RR-TB). We estimated the global burden of RR-TB over the lifetime of affected individuals. We synthesized data on incidence, case detection, and treatment outcomes in 192 countries (99.99% of global tuberculosis). Using a mathematical model, we projected disability-adjusted life years (DALYs) over the lifetime for individuals developing tuberculosis in 2020 stratified by country, age, sex, HIV, and rifampicin resistance. Here we show that incident RR-TB in 2020 was responsible for an estimated 6.9 (95% uncertainty interval: 5.5, 8.5) million DALYs, 44% (31, 54) of which accrued among TB survivors. We estimated an average of 17 (14, 21) DALYs per person developing RR-TB, 34% (12, 56) greater than for rifampicin-susceptible tuberculosis. RR-TB burden per 100,000 was highest in former Soviet Union countries and southern African countries. While RR-TB causes substantial short-term morbidity and mortality, nearly half of the overall disease burden of RR-TB accrues among tuberculosis survivors. The substantial long-term health impacts among those surviving RR-TB disease suggest the need for improved post-treatment care and further justify increased health expenditures to prevent RR-TB transmission.

---

### Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis [^114QSSKT]. The Lancet: Respiratory Medicine (2015). Medium credibility.

Results

Of the one million potential TB epidemics we simulated, 315,567 simulations had plausible TB incidence and prevalence for a medium-to-high burden setting and were retained for consideration. Figure 2 shows the estimated proportion of incident MDR-TB representing transmission of resistance rather than selection of resistance during previous treatment in each of those 315,567 "plausible" simulations (see also Figure S2). In the 15% of these plausible simulations in which fewer than half of MDR infections resulted from transmission, the ratio of MDR prevalence among retreatment versus new notifications was extraordinarily high (median 37, IQR 24–61). Among the remaining 85% of plausible simulations, the retreatment-to-new MDR prevalence ratio was 7 (IQR 4–12), similar to the reported median ratio of 6 (IQR 5–11) across WHO notifications in 2013 from all countries with TB incidence > 40/100,000/year and > 10 cases/year.

---

### The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the end TB era [^113ByTEh]. The Lancet: Respiratory Medicine (2018). Medium credibility.

Tuberculosis is the number one cause of death from infectious disease globally and drug-resistant forms of the disease are a major risk to global health security. On the occasion of World Tuberculosis Day (March 24, 2018), we provide an up-to-date review of the status of the tuberculosis epidemic, recommended diagnostics, drug treatments and vaccines, progress in delivery of care and prevention, progress in research and development, and actions needed to accelerate progress. This Review is presented in the context of the UN Sustainable Development Goals and WHO's End TB Strategy, which share the aim of ending the global tuberculosis epidemic. In 2016, globally there were an estimated 10.4 million new cases of tuberculosis, and 600000 new cases with resistance to rifampicin (the most powerful first-line drug). All countries and age groups are affected by tuberculosis, but most cases (90%) in 2016 were in adults, and almost two-thirds were accounted for by seven countries: India, Indonesia, China, Philippines, Pakistan, South Africa, and Nigeria. The sex ratio (male to female) was 1.9 and 10% of patients with newly diagnosed tuberculosis were also HIV-positive. There were 1.7 million deaths from tuberculosis in 2016, including 0.4 million deaths among people co-infected with HIV (officially classified as deaths caused by HIV/AIDS). Progress in care and prevention means that the global mortality rate (deaths per 100000 people per year) is decreasing by 3.4% per year and incidence (new cases per 100000 people per year) is decreasing by 1.9% per year. From 2000 to 2016, the annual global number of tuberculosis deaths decreased by 24% and the mortality rate declined by 37%. Worldwide, an estimated 53 million deaths were averted through successful treatment. Nonetheless, major gaps in care and prevention remain. For example, the 6.3 million new cases of tuberculosis reported globally in 2016 represented only 61% of the estimated incidence; only one in five of the estimated number of people with drug-resistant tuberculosis was enrolled in treatment. Pipelines for new diagnostics, drugs, and vaccines are progressing, but slowly. Actions needed to accelerate progress towards global milestones and targets for reductions in the burden of tuberculosis disease set for 2020, 2025, 2030, and 2035 include closing coverage gaps in testing, reporting of cases, and overall access to health care, especially in countries that account for the largest share of the global gap; multisectoral efforts to reduce prevalence of major risk factors for infection and disease; and increased investment in research and development.

---

### Biology, behavior and policy, or, dr. fauci, sen. paul and prof. lucas walk into a pandemic [^1143fxa2]. EClinicalMedicine (2021). Medium credibility.

A little math can help. In a standard, simple epidemiological model, the population threshold for herd immunity, commonly denoted, is given by the formulawhere R₀ is the basic reproduction number and refers to the expected number of secondary cases that result from one infected case.

For an extremely contagious disease like measles, R₀ might be about 10, leading to a p of about 0.9, which is why attaining high rates of immunization is so important. For a much less contagious disease, the threshold is lower. For example, if R₀ = 1.2, then p = 0.17. Once more than 17% of the population is immune, whether through infection or from vaccination, we expect the disease to die out. The details change in more complex models, for example if different sub-populations spread the disease at different rates, or if acquired immunity is only partial, but the basic insight is the same: the less infectious a disease is, the lower the herd immunity threshold.

While this insight is correct, it is easy to make two conceptual mistakes. The first mistake would be to assume that R0 is a fixed, intrinsic biological property of a disease. While some diseases are inherently more contagious than others, R0 is a result of both biology (i.e. duration of being contagious, risk of infection for a given level of exposure) but also of environment and behavior (i.e. contact rate between susceptible and infected individuals, amount of exposure when a contact occurs). This is why we should wear masks, maintain physical distance, meet other people outdoors rather than indoors whenever feasible, and so on: even if we cannot change the inherent infectiousness of the disease, we can still reduce R0.

The second mistake would be to forget the Lucas critique: even if we concede that the low share of previously infected people exceeded a herd immunity threshold, it does not follow that we can use this observation to argue for fewer restrictions on activity, or to tell the public that fewer precautions are needed. If indeed the herd immunity threshold was low, it is likely that this was in large part because public policy and private behavior contributed to keeping R₀ low. Policies such as shelter-in-place orders have successfully reduced mobility and COVID-19 transmission across the US. If we were to change policy or encourage less cautious private behavior, R₀ would likely increase, and the herd immunity threshold would increase as well.

---

### Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis [^117FqQF3]. The Lancet: Respiratory Medicine (2015). Medium credibility.

Sensitivity analyses

For each model parameter, we computed partial rank correlation coefficients for the correlation of the parameter (simultaneously adjusted for all other model parameters) with the percentage of MDR incidence that resulted from MDR transmission rather than MDR acquisition during prior treatment in the same individual. We computed these correlation coefficients among all plausible simulations for a medium-to-high-TB-burden country as described above, and, for each of the six representative countries shown in Table 2, among the subset of simulations that fell within that country's WHO-reported uncertainty intervals for each of the four notification measures considered, as shown in Table 2. We also performed illustrative sensitivity analysis for the variation in a specific parameter (rate of TB diagnosis and treatment initiation) between individual countries, by restricting our set of simulations based on country-level estimates of that parameter and recalculating our primary result (see Supplementary material).

Then, in addition to the sensitivity analyses noted above related to time since MDR emergence and availability of second-line MDR treatment, we also considered the impacts of non-equilibrium TB epidemiology and of epidemic heterogeneity. To evaluate the impact of the declining overall TB incidence seen over the past decade in much of the world, we first reduced the TB reactivation rate linearly by 2% per year and determined the resulting percent of incident MDR-TB that resulted from transmission. We then repeated a similar analysis in which the declining overall TB incidence instead results from a 1%/year linear decrease in the TB transmission rate. Both of these scenarios approximately replicated the observed 1.5% annual decline in TB incidence that is currently estimated. Finally, we tested the sensitivity of our results to our assumption of population homogeneity by evaluating the impact of MDR hotspots on the fraction of MDR-TB that results from MDR transmission. For each homogeneous-model simulation, we increased the acquisition and transmission of resistance within a hotspot, and decreased those of the background population, by random amounts, calibrating the hotspot population size to achieve equal average MDR incidence in the heterogeneous and homogeneous populations (details in supplement, section 1c). All analyses were performed in R version 3.1.2.

Role of the funding source

The funding sources had no role in study design, in collection, analysis, or interpretation of data, in the writing of the report, or in the decision to submit for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^115xg4pN]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Statistical Analysis

The analytic model was coded in R (version 3.5.2) and C++ via the Rcpp package (version 1.0.0). Bayesian evidence synthesis was used to calibrate models to data on population demography, TB epidemiology, and TB services (Figures E11A and E11B). Using this approach, uncertainty in study outcomes is represented by a large number of simulated epidemic trajectories, which were estimated using incremental mixture importance sampling via the IMIS package (version 0.1). Uncertainty in parameters not included in model calibration (e.g. unit costs and VSL estimates) was introduced by second-order Monte Carlo simulation. For each outcome of interest, point estimates were calculated as the mean value obtained from the distribution of simulated epidemic trajectories. Ninety-five percent uncertainty intervals were calculated as the 2.5th and 97.5th percentiles of the outcome distribution.

---

### Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study [^114CzfpD]. The Lancet: Global Health (2023). High credibility.

Despite the extensive literature review, few datapoints could directly inform parameters. By including data on transitions between minimal and clinical disease, and between minimal and infectious disease, we were able to restrict the likely parameter space. No usable data were available on consecutive state changes, which limited our ability to consider how different disease histories affect trajectories. As such, we assumed that transition rates were fixed regardless of disease history. While the chosen model structure will drive some of the results, limitations in the available data prohibit a more complicated model structure (appendix pp 3). Additionally, our three-state linear model structure is in line with historical and recent conceptualisations of the spectrum of tuberculosis disease.,

Our data and simulations start from prevalent disease (minimal, subclinical, and clinical) without knowledge of previous disease trajectory and a single rate of transition for all. As such the parameters represent a mix of both recent and more distal M tuberculosis infections, with some individuals who are rapidly progressing and some who are transitioning or on their way to recovery. However, this mix of new and old disease is a reflection of current prevalent tuberculosis states in a population, as found in prevalence surveys. Prevalent disease is the immediate driver of tuberculosis morbidity, mortality, and transmission, and, as such, the population that tuberculosis policies look to address.

In summary, our estimates show that only around half of all people with subclinical tuberculosis disease will progress to clinical disease, representing a flaw in the assumption that targeting clinical disease will enable care for all individuals with tuberculosis disease or interrupt transmission from infectious disease. Our work also highlights an important question regarding where the threshold should be set for tuberculosis disease that requires treatment. Although the current threshold of infectious disease can be relatively easily confirmed, minimal (ie, microbiologically negative) disease can persist after regression from subclinical disease, and has a substantial risk of re-progression. Through this work, we can more reliably quantify the potential population benefits of addressing subclinical or even minimal disease. Such interventions are needed to comprehensively interrupt, or even prevent transmission, which remains a global, yet elusive, target.

---

### Counting the lives saved by DOTS in India: a model-based approach [^114dJYGL]. BMC Medicine (2017). Low credibility.

Background

Against the backdrop of renewed efforts to control tuberculosis (TB) worldwide, there is a need for improved methods to estimate the public health impact of TB programmes. Such methods should not only address the improved outcomes amongst those receiving care but should also account for the impact of TB services on reducing transmission.

Methods

Vital registration data in India are not sufficiently reliable for estimates of TB mortality. As an alternative approach, we developed a mathematical model of TB transmission dynamics and mortality, capturing the scale-up of DOTS in India, through the rollout of the Revised National TB Control Programme (RNTCP). We used available data from the literature to calculate TB mortality hazards amongst untreated TB; amongst cases treated under RNTCP; and amongst cases treated under non-RNTCP conditions. Using a Bayesian evidence synthesis framework, we combined these data with current estimates for the TB burden in India to calibrate the transmission model. We simulated the national TB epidemic in the presence and absence of the DOTS programme, measuring lives saved as the difference in TB deaths between these scenarios.

Results

From 1997 to 2016, India's RNTCP has saved 7.75 million lives (95% Bayesian credible interval 6.29–8.82 million). We estimate that 42% of this impact was due to the 'indirect' effects of the RNTCP in averting transmission as well as improving treatment outcomes.

Conclusions

When expanding high-quality TB services, a substantial proportion of overall impact derives from preventive, as well as curative, benefits. Mathematical models, together with sufficient data, can be a helpful tool in estimating the true population impact of major disease control programmes.

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^116eDox8]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

TB Cases Averted

In the base-case scenario, 148,352 (95% uncertainty interval, 127,065–173,106) U.S. TB cases are projected for the 2020–2035 period (32,810 [95% uncertainty interval, 28,396–37,286] U.S.-born and 115,541 [95% uncertainty interval, 96,385–136,823] non–U.S.-born). Table 1 shows total U.S. TB cases averted over the period of 2020–2035 for optimistic and pessimistic scenarios compared with the base-case scenario, for countries individually, for the top five countries, and for all countries collectively (Table E2 shows results for the top 30 countries). The countries with the highest number of TB cases averted under the optimistic scenario — Mexico and the Philippines — were those projected to contribute a large number of future migrants to the United States that currently have flat or rising TB incidence trends. The countries with the highest number of additional TB cases in the pessimistic scenario — Vietnam, China, and India — were those with rapidly declining current TB incidence trends. The 39,795 (95% uncertainty interval, 28,603–55,142) TB cases averted if all countries achieve the WHO End TB Strategy targets represent 27% (95% uncertainty interval, 21–34%) of all TB cases projected for the base-case scenario over 2020–2035. Of these averted cases, 7.1% (95% uncertainty interval, 5.9–8.6%) were projected to result from secondary infections averted among U.S.-born individuals, and 59% (95% uncertainty interval, 53–65%) of this reduction could be achieved if the top five countries achieved the WHO End TB Strategy targets.

Table 1.
Cumulative TB Cases Averted during 2020–2035 for Optimistic and Pessimistic Scenarios Compared with the Base-Case Scenario

Table E3 extends these results to include reductions in lifetime TB cases occurring after the end of 2035. In general, these values are 30–35% higher than those in Table 1, with 52,770 (95% uncertainty interval, 38,044–71,693) cases averted by the optimistic scenario over this extended time horizon.

---

### American Thoracic Society / centers for disease control and prevention / Infectious Diseases Society of America: controlling tuberculosis in the United States [^1141kWMW]. American Journal of Respiratory and Critical Care Medicine (2005). Medium credibility.

Box 1 — major challenges to successful control of tuberculosis (TB) in the United States include TB among foreign-born persons residing in the United States, delays in detection and reporting of cases of pulmonary TB, deficiencies in protecting contacts of persons with infectious TB and in preventing and responding to TB outbreaks, presence of a large reservoir of persons living in the United States with latent TB infection (LTBI) who are at risk for progression to TB disease, and maintaining clinical and public health expertise in an era of declining TB incidence; these five concerns serve as the focal point for the recommendations made in this statement to control and prevent TB in the United States.

---

### Estimating the population at high risk for tuberculosis through household exposure in high-incidence countries: a model-based analysis [^115dfcLJ]. EClinicalMedicine (2021). Medium credibility.

2 Methods

2.1 Overview

This model-based estimation study analyzes age-, sex-, and location-specific estimates of TB burden from GBD 2019 together with an age-, sex-, and location-specific household composition analysis to generate comparable estimates of the population (by age and sex) exposed to someone with new pulmonary TB in their household in 20 countries in 2019. We selected the countries for modelling to include those among the top 20 countries for TB incidence counts in GBD 2017.

This analysis complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement. We conducted estimation using Python version 3.6 and published a code repository. The analysis uses publicly available de-identified data and did not require participant consent or human subjects review.

2.2 Data sources

We extracted results from GBD 2019 to inform the age-, sex-, and location- specific population and active TB incidence for each modelled country in 2019. We conducted our primary analysis using incident cases in 2019 and a supplemental analysis modelled using prevalent cases to align with different public health intervention scenarios. The methodology for population and disease burden estimation for GBD 2019 is described elsewhere. We used age-, sex-, and location-specific estimates of pulmonary TB cases from GBD 2019 to include only cases of pulmonary TB (and exclude extrapulmonary TB) from our subsequent estimation (Fig S1). The GBD 2019 process calculated the proportions of pulmonary versus extrapulmonary TB using WHO case notification data and a spatiotemporal Gaussian process regression. We included active pulmonary TB among people living with HIV and people without HIV. We extracted data on household composition by age and sex from the most recent Demographic and Health Survey (DHS) or Integrated Public Use Microdata Series (IPUMS) available for each country (Table S1). We used the sample of households from the most recent available data source in each location to approximate the probability of each household size and age/sex composition, as described below.

---

### Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study [^111fAYtb]. The Lancet: Global Health (2023). High credibility.

Background

Prevalence surveys show a substantial burden of subclinical (asymptomatic but infectious) tuberculosis, from which individuals can progress, regress, or even persist in a chronic disease state. We aimed to quantify these pathways across the spectrum of tuberculosis disease.

Methods

We created a deterministic framework of untreated tuberculosis disease with progression and regression between three states of pulmonary tuberculosis disease: minimal (non-infectious), subclinical (asymptomatic but infectious), and clinical (symptomatic and infectious). We obtained data from a previous systematic review of prospective and retrospective studies that followed and recorded the disease state of individuals with tuberculosis in a cohort without treatment. These data were considered in a Bayesian framework, enabling quantitative estimation of tuberculosis disease pathways with rates of transition between states and 95% uncertainty intervals (UIs).

Findings

We included 22 studies with data from 5942 individuals in our analysis. Our model showed that after 5 years, 40% (95% UI 31.3–48.0) of individuals with prevalent subclinical disease at baseline recover and 18% (13.3–24.0) die from tuberculosis, with 14% (9.9–19.2) still having infectious disease, and the remainder with minimal disease at risk of re-progression. Over 5 years, 50% (40.0–59.1) of individuals with subclinical disease at baseline never develop symptoms. For those with clinical disease at baseline, 46% (38.3–52.2) die and 20% (15.2–25.8) recover from tuberculosis, with the remainder being in or transitioning between the three disease states after 5 years. We estimated the 10-year mortality of people with untreated prevalent infectious tuberculosis to be 37% (30.5–45.4).

Interpretation

For people with subclinical tuberculosis, classic clinical disease is neither an inevitable nor an irreversible outcome. As such, reliance on symptom-based screening means a large proportion of people with infectious disease might never be detected.

Funding

TB Modelling and Analysis Consortium and European Research Council.

---

### American Thoracic Society / centers for disease control and prevention / Infectious Diseases Society of America: controlling tuberculosis in the United States [^115KnkCT]. American Journal of Respiratory and Critical Care Medicine (2005). Medium credibility.

Basic principles of TB control — United States goal and core strategies focus on preventing transmission and progression from latent infection. "The goal of TB control in the United States is to reduce morbidity and mortality caused by TB by (1) preventing transmission of M. tuberculosis… and (2) preventing progression from LTBI to TB disease… " "Four fundamental strategies are used to achieve this goal… as follows: Early and accurate detection, diagnosis, and reporting of TB cases leading to initiation and completion of treatment; Identification of contacts of cases of infectious TB and treatment of those at risk with an effective drug regimen; Identification of other persons with LTBI at risk for progression to TB disease and treatment of those persons with an effective drug regimen". Within these strategies, "A suspected or confirmed case of TB should be reported immediately to the jurisdictional public health agency". "The evaluation of contacts of persons with infectious TB is one of the most productive methods of identifying adults and children with LTBI at high risk for progression to TB disease and persons in the early stages of TB disease", and "Targeted testing is intended to identify persons other than TB contacts who have increased risk for acquiring TB and to offer such persons diagnostic testing for M. tuberculosis infection and treatment, if indicated, to prevent subsequent progression to TB disease".

---

### Current and future trends in tuberculosis incidence in New York city: a dynamic modelling analysis [^112cVnhA]. The Lancet: Public Health (2017). Medium credibility.

Background

After steady decline since the 1990s, tuberculosis (TB) incidence in New York City (NYC) and the United States (US) has flattened. The reasons for this trend and the implications for the future trajectory of TB in the US remain unclear.

Methods

We developed a compartmental model of TB in NYC, parameterized with detailed epidemiological data. We ran the model under five alternative scenarios representing different explanations for recent declines in TB incidence. We evaluated each scenario's relative likelihood by comparing its output to available data. We used the most likely scenarios to explore drivers of TB incidence and predict future trajectories of the TB epidemic in NYC.

Findings

Demographic changes and declining TB transmission alone were insufficient to explain recent trends in NYC TB incidence. Only scenarios that assumed contemporary changes in TB dynamics among the foreign-born - a declining rate of reactivation or a decrease in imported subclinical TB - could accurately describe the trajectory of TB incidence since 2007. In those scenarios, the projected decline in TB incidence from 2015 to 2025 varied from minimal [2.0%/year (95% credible interval 0.4–3.5%)] to similar to 2005 to 2009 trends [4.4%/year (2.5–6.4%)]. The primary factor differentiating optimistic from pessimistic projections was the degree to which improvements in TB dynamics among the foreign-born continued into the coming decade.

Interpretation

Further progress against TB in NYC requires additional focus on the foreign-born population. Absent additional intervention in this group, TB incidence may not decline further.

---

### American Thoracic Society / centers for disease control and prevention / Infectious Diseases Society of America: controlling tuberculosis in the United States [^114zE1R3]. American Journal of Respiratory and Critical Care Medicine (2005). Medium credibility.

Box 4 — strategies to achieve the goal of reduction of TB morbidity and mortality summarize priority actions: early and accurate detection, diagnosis, and reporting of TB cases; prompt initiation of effective treatment and completion of a full course of therapy for patients with TB; identification of contacts of patients with infectious TB and other persons with latent TB infection who are at substantial risk for progression to TB disease and treatment of those persons who are at substantial risk; and identification of settings in which a high risk exists for transmission of M. tuberculosis and application of effective infection-control measures.

---

### Potential impact of tuberculosis vaccines in China, south Africa, and India [^114MAung]. Science Translational Medicine (2020). Medium credibility.

More effective tuberculosis vaccines are needed to help reach World Health Organization tuberculosis elimination goals. Insufficient evidence exists on the potential impact of future tuberculosis vaccines with varying characteristics and in different epidemiological settings. To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries. We calibrated Mycobacterium tuberculosis (M.tb) transmission models to age-stratified demographic and epidemiological data from China, South Africa, and India. We varied vaccine efficacy to prevent infection or disease, effective in persons M.tb uninfected or infected, and duration of protection. We modeled routine early-adolescent vaccination and 10-yearly mass campaigns from 2025. We estimated median percentage population-level tuberculosis incidence rate reduction (IRR) in 2050 compared to a no new vaccine scenario. In all settings, results suggested vaccines preventing disease in M.tb -infected populations would have greatest impact by 2050 (10-year, 70% efficacy against disease, IRR 51%, 52%, and 54% in China, South Africa, and India, respectively). Vaccines preventing reinfection delivered lower potential impact (IRR 1, 12, and 17%). Intermediate impact was predicted for vaccines effective only in uninfected populations, if preventing infection (IRR 21, 37, and 50%) or disease (IRR 19, 36, and 51%), with greater impact in higher-transmission settings. Tuberculosis vaccines have the potential to deliver substantial population-level impact. For prioritizing impact by 2050, vaccine development should focus on preventing disease in M.tb -infected populations. Preventing infection or disease in uninfected populations may be useful in higher transmission settings. As vaccine impact depended on epidemiology, different development strategies may be required.

---

### Ecology, global diversity and evolutionary mechanisms in the Mycobacterium tuberculosis complex [^1145iiFQ]. Nature Reviews: Microbiology (2025). High credibility.

With the COVID-19 pandemic receding, tuberculosis (TB) is again the number one cause of human death to a single infectious agent. TB is caused by bacteria that belong to the Mycobacterium tuberculosis complex (MTBC). Recent advances in genome sequencing have provided new insights into the ecology and evolution of the MTBC. This includes the discovery of new phylogenetic lineages within the MTBC, a deeper understanding of the host tropism among the various animal-adapted lineages, enhanced knowledge on the evolutionary dynamics of antimicrobial resistance and transmission, as well as a better grasp of the within-host MTBC diversity. Moreover, advances in long-read sequencing are increasingly highlighting the relevance of structural genomic variation in the MTBC. These findings not only shed new light on the biology and epidemiology of TB, but also give rise to new questions and research avenues. The purpose of this Review is to summarize these new insights and discuss their implications for global TB control.

---

### Feasibility of achieving the 2025 WHO global tuberculosis targets in south Africa, China, and India: a combined analysis of 11 mathematical models [^114h1GkX]. The Lancet: Global Health (2016). Medium credibility.

Summary

Background

The post-2015 End TB Strategy proposes targets of 50% reduction in tuberculosis incidence and 75% reduction in mortality from tuberculosis by 2025. We aimed to assess whether these targets are feasible in three high-burden countries with contrasting epidemiology and previous programmatic achievements.

Methods

11 independently developed mathematical models of tuberculosis transmission projected the epidemiological impact of currently available tuberculosis interventions for prevention, diagnosis, and treatment in China, India, and South Africa. Models were calibrated with data on tuberculosis incidence and mortality in 2012. Representatives from national tuberculosis programmes and the advocacy community provided distinct country-specific intervention scenarios, which included screening for symptoms, active case finding, and preventive therapy.

Findings

Aggressive scale-up of any single intervention scenario could not achieve the post-2015 End TB Strategy targets in any country. However, the models projected that, in the South Africa national tuberculosis programme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral therapy, expanded facility-based screening for symptoms of tuberculosis at health centres, and improved tuberculosis care could achieve a 55% reduction in incidence (range 31–62%) and a 72% reduction in mortality (range 64–82%) compared with 2015 levels. For India, and particularly for China, full scale-up of all interventions in tuberculosis-programme performance fell short of the 2025 targets, despite preventing a cumulative 3.4 million cases. The advocacy scenarios illustrated the high impact of detecting and treating latent tuberculosis.

Interpretation

Major reductions in tuberculosis burden seem possible with current interventions. However, additional interventions, adapted to country-specific tuberculosis epidemiology and health systems, are needed to reach the post-2015 End TB Strategy targets at country level.

Funding

Bill and Melinda Gates Foundation

---

### The potential impact of preventive therapy against tuberculosis in the WHO south-east Asian region: a modelling approach [^112X9jji]. BMC Medicine (2020). Medium credibility.

Nonetheless, options for preventive therapy have seen important developments in recent years. Isoniazid preventive therapy (IPT) involves 6 months daily treatment with isoniazid, and could lower the risk of active TB by 60%, amongst those with latent TB infection. More recent developments include 3HR (isoniazid and rifampicin daily for 3 months), 3HP (isoniazid and rifapentine once weekly for 3 months) and 1HP (isoniazid and rifapentine once weekly for 1 month), all regimen options achieving non-inferior effectiveness to IPT, with shortened and simplified treatment. These and future regimens may offer new opportunities to accelerate uptake of TB prevention, in line with WHO recommendations.

In this context, strategic planning could benefit from estimation of the potential epidemiological impact of preventive therapy. In the present work, we aimed to address this need, using dynamical mathematical models. We concentrated on the WHO South-East Asian (SEA) Region, estimated to account for > 30% of global prevalence of latent TB infection and 44% of global TB incidence, the highest of any of the WHO regions. We developed mathematical models of TB transmission, calibrated to the TB epidemic in each of the 11 countries in the region. Using this framework, we estimated the potential reductions in TB incidence and mortality that could be achieved by 2030, with implementation of WHO guidelines in each of the 11 countries in the region.

---

### NTCA guidelines for respiratory isolation and restrictions to reduce transmission of pulmonary tuberculosis in community settings [^1151EF4C]. Clinical Infectious Diseases (2024). High credibility.

NTCA community respiratory isolation — modeling evidence on transmission: Three modeling studies offered indirect evidence that isolation interventions, when combined with other transmission-prevention measures, may reduce transmission of TB, but many assumptions were required, including the duration of infectiousness.

---

### Latent TB infection resource hub | Tuberculosis (TB)… [^115xADd9]. CDC (2025). Medium credibility.

At a glance The online latent TB infection resource hub is a one-stop shop for resources related to: How to Order Materials Materials are available free of charge for order via CDC Publications on Demand. Featured Resources. Resources for Providers This statement from the Advisory Council for the Elimination of Tuberculosis updates the strategy to eliminate TB in the United States. The report provides new recommendations to prevent TB, specifically through focus on identifying individuals at risk and testing and treating latent TB infection. The U. S. Preventive Services Task Force makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.

These updated 2020 latent TB infection treatment guidelines include the NTCA- and CDC-recommended treatment regimens that comprise three preferred rifamycin-based regimens and two alternative monotherapy regimens with daily isoniazid. CDC continues to recommend 3HP for treatment of latent TB infection in adults and now recommends use of 3HP 1) in persons with latent TB infection aged 2–17 years; 2) in persons with latent TB infection who have HIV infection, including acquired immunodeficiency syndrome, and are taking antiretroviral medications with acceptable drug-drug interactions with rifapentine; and 3) by DOT or self-administered therapy in persons aged ≥ 2 years. These guidelines are intended for clinicians, other health care providers, patients with HIV, and policy makers in the United States. Resources for Patients Information and tools for patients receiving treatment for latent TB infection. Many resources are available in multiple languages.

---

### Estimating the population at high risk for tuberculosis through household exposure in high-incidence countries: a model-based analysis [^114VhdHr]. EClinicalMedicine (2021). Medium credibility.

Background

Household contacts of people with pulmonary tuberculosis (TB) have greater risk of developing TB. Recent guidelines conditionally recommended TB preventive treatment (TPT) for household contacts of any age living in TB high-incidence countries, expanding earlier guidance to provide TPT to household contacts under five. The all-age population of household contacts has not been estimated.

Methods

Our model-based estimation included 20 countries with > 80% of incident TB globally in 2019. We developed country-specific distributions of household composition by age and sex using bootstrap resampling from health surveys and census data. We incorporated age-, sex-, year-, and location-specific estimates of pulmonary TB incidence from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 to estimate the population in each country sharing a household with someone with incident pulmonary TB, and quantified uncertainty using a Monte Carlo approach.

Findings

We estimate that 38 million [95% uncertainty interval (UI) 33–43 million] individuals lived in a household with someone with incident pulmonary TB in 2019 in these 20 countries. Children under five made up 12% of the population with household exposure, while adults were 65%. Zimbabwe, Mozambique, Zambia, and Pakistan had the highest proportion of the population with household exposure, while India had the highest number of contacts (11.4 million, 95% UI 9.7–13.4 million).

Interpretation

Expanding TPT evaluation to household contacts of all ages in high-incidence countries could include a population more than 7-times larger than the under-5 contacts previously prioritized. This would substantially increase the impact of household contact investigation on reducing TB morbidity and mortality.

Funding

JMR is supported by the National Institute of Allergy and Infectious Diseases (K01 AI138620). This research was funded in part by a 2020 developmental grant from the University of Washington / Fred Hutch Center for AIDS Research, an NIH funded program under award number AI027757 which is supported by the following NIH Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK. This work was funded in part by the National Science Foundation (DMS-1839116).

---

### Impact of effective global tuberculosis control on health and economic outcomes in the United States [^111Un4qg]. American Journal of Respiratory and Critical Care Medicine (2020). Medium credibility.

Discussion

TB is concentrated in low- and middle-income countries, and disparities between rich and poor countries have grown in recent years. These disparities, combined with migration from low- to high-income countries, mean that large numbers of individuals migrate to countries where Mtb exposure is orders of magnitude lower than in their birth countries. These individuals face lower TB risks than in their birth countries but higher risks than native-born individuals. The net effect for high-income countries is that TB is increasingly concentrated among migrant populations, with population TB trends sensitive to changes in migrant population size and Mtb exposure.

Our study describes what could happen in the United States if TB control efforts are substantially improved — or stagnate — in the countries from which individuals migrate to the United States. In our optimistic scenario, in which all countries reduce TB incidence rates by 90% between 2015 and 2035, we predict 40,000 (95% uncertainty interval, 29,000–55,000) fewer U.S. TB cases between 2020 and 2035 or 53,000 (95% uncertainty interval, 38,000–72,000) fewer TB cases including lifetime outcomes. Extrapolating incidence trends achieved in the optimistic scenario produces a high probability that the United States would reach the preelimination target of less than 1.0 TB case per 100,000 by 2050. In the base-case scenario, this threshold is unlikely to be reached before 2100. These impacts can be benchmarked against prior analyses examining radically strengthened TB services within the United States in which large improvements in TB and LTBI detection and treatment were projected to have an impact on TB incidence approximately equal to that projected for the optimistic scenario. Even if the optimistic scenario is restricted to the top five countries (Mexico, the Philippines, India, Vietnam, and China), the reduction in TB incidence by 2035 is substantial, with 24,000 (95% uncertainty interval, 16,000–34,000) TB cases averted during 2020–2035.